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1  Abbreviations 
Table 1: Abbreviations (in alphabetic order)
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AILT
ALL
AML
AMN Associated  malignant neoplasm
CLL
CML
DLBL Diffuse large B cell lymphoma
EBV Epstein-Barr virus
FL Follicular lymphoma
HCL 
HIV Human immunodeficiency virus
HL Hodgkin lymphoma
HPSCD
LBL
LDHL Lymphocyte depleted Hodgkin lymphoma
LPL 
MCHL 
MCL Mantle cell lymphoma
MDS 
MM
MPD
NHL Non Hodgkin lymphoma
NLPHL Nodular lymphocyte predominant Hodgkin lymphoma
NOS Not otherwise specified
NSHL Nodular sclerosis Hodgkin lymphoma
RR Relative risk
SIR Standardized incidence ratio 
SLL 
SMN Second malignant neoplasm
Angioimmunoblastic T cell lymphoma
Acute lymphocytic leukaemia
Acute myeloid leukaemia
Chronic lymphoid leukaemia
Chronic myeloid leukaemia
Hairy cell leukaemia
Haematopoietic stem cell disease
Lymphoblastic lymphoma
Lymphoplasmacytic lymphoma
Mixed cellularity Hodgkin lymphoma
Myelodysplastic syndrome
Multiple myeloma
Myeloproliferative disease
Small cell lymphocytic lymphoma
2  Summary 
2.1  Introduction 
Numerous  studies  document  that  lymphoid  and  haematopoietic  tumours  and  their  therapy 
increase the risk of second malignant neoplasms [1]-[22]. The reverse, a study of the incidence 
of  lymphoid  and  haematological  tumours  after  a  diagnosis  of  solid  cancer  has  rarely  been 
performed [23].  We undertook this  study to  analyse  the  incidence of  associated  neoplasms 
preceding and following the diagnosis of cancers of lymphoid and haematopoietic tissues.
2.2  Materials and Methods 
The data of the cancer registry of the Canton of Zurich (population of 1.3 million) was our source. 
12'798 patients with one or more than one cancer of haematopoietic and lymphoid tissues, had 
been recorded between January 1980 to June 2008. 
2.3  Results 
In total we detected 2'885 previous and subsequent associated malignant neoplasms (AMN) in 
12'798 patients. In the order of descending frequency, 433 cancers of prostate, 354 cancers of 
breast,  295  cancers  of  colorectum and  227  cancers  of  lung  were  detected.  After  excluding 
patients with more than one cancer of haematopoietic and lymphoid tissues, we detected 2'374 
previous and subsequent AMN in 10'923 patients. 
205 in 1'000 lymphohaematopoetic cancers are associated with another cancer. Solid and non 
solid AMN were mostly associated with indolent B cell lymphomas and Hodgkin lymphomas (HL) 
(237/1'000 cases for both). 
Statistical analyses showed a most significant increase of AMN as before and after HL. Statistical 
analyses using a generalized additive model  for  Poisson regression confirmed this increase. 
AMN  among  HL patients  were  mostly  cancer  of  breast,  bronchus  and  lung,  prostate  and 
colorectum. 
Up to 25% of women with HL diagnosed between 20 and 30 years old developed a previous or 
subsequent solid cancer in the study period from 1980 and 2008. Almost 30% of women with HL 
diagnosed between 65 and 74 years old had a previous solid AMN in the study period from 1980 
and 2008. Particulary 17% of women with HL diagnosed between 65 and 69 years old had a  
previous cancer of breast in the study period from 1980 and 2008 (versus 4% in all women with  
tumours of haematopoietic and lymphoid tissues diagnosed between 65 and 69 years old). 
The relative risk (RR) of previous solid malignant neoplasm in HL patients compared to patients  
with all other tumours of haematopoietic and lymphoid tissues (except HL) diagnosed between 
65 and 69 years old is 2,29 among women and 1,31 among men. The RR of previous breast  
cancer  in  HL patients  compared  to  patients  with  all  other  tumours  of  haematopoietic  and 
lymphoid tissues (except HL) diagnosed between 65 and 69 years old is 3,80.
2.4  Conclusion 
In this population-based study we could show that HL that occurred early in life, are associated 
with later malignancies. But HL are also associated with previous malignant neoplasms including 
breast, lung, prostate and colorectum cancers when HL occur later in life. The reason for this  
association  of  previous  malignant  tumours  with  later  HL may  include  common  genetic  risk 
factors, direct genotoxic therapy effects and immunomodulation due to therapy or due to the 
cancer itself.
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3  Introduction 
3.1  Definition and classification of tumours of haematopoietic and lymphoid tissues 
3.1.1  WHO classification 
Neoplasms originating in the  haematopoietic and lymphoid tissues consist  of  several  closely 
related groups of neoplasms. The World Health Organization (WHO) classification of tumours of 
haematopoietic  and  lymphoid  tissues  [24]. renewed  in  2008  is  based  on  a  biological 
classification. Unlike the epidemiologic taxonomy used in numerous epidemiological studies, this 
classification classifies neoplasms primarily according to their lineage (e.g. myeloid or lymphoid 
origin) [24].
3.1.2  Subdivisions in categories 
Haematopoietic  and  lymphoid  tumours  are  subdivided  into  6  groups  according  to  their 
morphology,  immunophenotype,  genetic  and clinical  characteristics:  chronic  myeloproliferative 
diseases, myelodysplastic syndromes, acute myeloid and lymphoid leukaemias, neoplasms of 
mature B cell, Hodgkin lymphomas and T cell/natural killer cell neoplasms [24].
3.2  Incidences of tumours of haematopoietic and lymphoid tissues 
3.2.1  Geographic incidence 
In 2006 the fraction of non Hodgkin lymphoma (NHL) in Western Europe (European economic 
area and Switzerland) represented 3.2% of all cancers (74'800 cases of NHL). The fraction of 
leukaemia represented 2.6% of all cancers (61'400 cases of leukaemias) [25].
From 1985 to  2004 50’066 new cases of  lymphoid and haematopoietic  tumours have been 
reported in Switzerland. On average, 2’503 new cases have been diagnosed per year [26].
3.2.2  Age specific incidence 
The incidence of NHL typically increases exponentially with the average age of diagnosis. In  
contrast,  the  incidence  of  HL shows  typically  two  peaks  depending  on  age:  the  first  peak 
between the age of 20 and 25 years and the second peak between 75 and 80 years  [27]. In 
Switzerland (1993-2004), 68% of HL are diagnosed between 0-49 years of age. NHL, multiple 
myelomas (MM) and leukaemias are diagnosed mostly in patients over 70 years old (>70 years: 
45% of NHL, 57% of MM and 46% of leukaemias) [26].
3.2.3  Gender specific incidence 
Lymphoid and haematopoietic tumours occur more frequently in the male population [27].
3.2.4  Trends in incidence 
A steady increase has been observed over the last decades in almost all haematopoietic and 
lymphoid neoplasms [28]. The reason for this trend is unknown. The occurrence of HIV 
associated-NHL in the 1980's only partially explains this increase [29]. 
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3.2.5  Incidence variations between subtypes 
Furthermore the incidence, average age at diagnosis and sex ratio vary between different types 
of  lymphoid  and  haematopoietic  tumours.  This  has  been  suggested  to  be  due  to  different 
etiological factors [28][30].
These  etiological  factors  include  genetic  factors,  immunosuppression,  infections,  medical 
therapy as well as lifestyle and occupational exposures. 
3.3  Etiologies of tumours of haematopoietic and lymphoid tissues 
3.3.1  Genetic factor and tumours of haematopoietic and lymphoid tissues 
The  most  commonly  described  mutations  associated  with  tumours  of  haematopoietic  and 
lymphoid tissues are:
● t (14;18) chromosomal translocation associated with follicular lymphoma (FL) [31]
● t (8;14) chromosomal translocation associated with Burkitt’s lymphoma [31]
● t (11;14) chromosomal translocation associated with mantle cell lymphoma (MCL) [32]
● t (9;22) chromosomal translocation associated with chronic myeloid leukaemia (CML) [31]
● trisomy 12 associated with small lymphocytic lymphoma (SLL) [31].
In addition to spontaneous translocations, mutations secondary to viral  infection and ionizing 
radiation can contribute to the formation of genetic mutations [33].
A familial increased risk has been observed for HL. A higher incidence is mostly seen in twins 
and siblings of HL patients diagnosed before the age of 50. A genetic susceptibility to HL could 
be attributed to HLA locus  [29]. In comparison the risk of NHL is only modestly increased in 
follow-up of first-degree relatives of patients with NHL [29]. There is evidence of chronic lymphoid 
leukaemia (CLL) running in families (especially in first degree relatives) but most cases do not  
have a familial link [34].
Certain inherited conditions, such as Fanconi anaemia can increase the risk of developing acute 
myeloid leukaemia (AML). Children with Down's syndrome are more likely to suffer from AML 
than other children [34].
Some specific germline mutations are associated with tumours of haematopoietic and lymphoid 
tissues  and  other  type  of  cancers.  For  example  the  germline  mutation  in  the  p53  tumour 
suppressor gene, as in Li-Fraumeni syndrome, is associated with breast cancers, soft  tissue 
sarcomas, osteosarcomas, brain tumors, acute leukaemias and adrenocortical tumours [35].
10
3.3.2  Lifestyle  and  occupational  exposure  and tumours  of  haematopoietic  and 
lymphoid tissues 
Pesticides, hair dyes, tobacco use, alcohol consumption and sun exposure have been proposed 
to contribute to the occurrence of NHL [33][36].
The role of tobacco and UV radiation is controversial.  In a few cohort  studies, smoking was 
linked  to  high-grade  NHL and  FL  [31].  Many  studies  have  shown  controversial  correlation 
between NHL and UV radiation that may be due to its immunosuppressive effect [37].
Longtime occupational exposure to benzene increases the risk of acute leukaemias (ALL, CML 
and AML) [34]. An increased overall lymphoma risk has been observed among architects, maids, 
farmers,  glass  formers  and  construction  workers.  In  the  occupational  group  analyses  of 
lymphoma  subentities,  HL  is  only  significantly  associated  with  rubber  and  plastic  products 
making.  Diffuse  large  B  cell  lymphoma (DLBL)  risk  is  considerably  increased  among metal  
processors.  Several  occupational  groups  (medical,  dental,  and  veterinary  workers;  sales 
workers; machinery fitters; and electrical fitters) showed an highly significant increased risk of FL. 
Farmers as well as agriculture and animal husbandry workers showed a particularly increased 
risk of MM [38].
3.3.3  Altered  immunological  function  and  tumours  of  haematopoietic  and  lymphoid 
tissues 
3.3.3.1  Primary and congenital immunodeficiencies 
Evidence  suggests  that  altered  immunological  function,  either  immunostimulation  or 
immunosuppression can be responsible for an increased risk of lymphoma [36]. 
The immunosuppression can be due to a primary congenital  immunodeficiency or an acquired 
immunodeficiency such as those encountered as side effects of immunosuppressive therapies,  
complications  following  certain  chronic  diseases  or  cancers,  particularly  tumours  of 
haematopoietic and lymphoid tissues [29]. 
Primary congenital immunodeficiencies caused by congenital X-linked immunodeficiency, ataxia-
telangiectasia and Wiskott–Aldrich syndrome are associated with NHL. NHL represents  one-to 
two-thirds of all cancers in this population [29][31]. 
3.3.3.2  Secondary and acquired immunosuppressions 
Acquired immunosuppression such as caused by auto-immune disease or immunosuppressive 
therapy is associated with an increased risk of NHL [29]. 
Patients with rheumatoid arthritis, systemic lupus erythematosus, Sjogren’s syndrome and celiac 
disease have been found to also have an increased risk of NHL [29][33][37].
Increased NHL occurrence has been described among patients treated with immunosuppressive 
drugs  (such  as  cyclosporin  and  azathioprine)  following  kidney,  heart  and  bone  marrow 
transplantation [29][31].  The  literature  also  shows  an  increased  risk  of  developing HL after 
allogenic bone marrow transplantation [29].
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3.3.4  Infection and tumours of haematopoietic and lymphoid tissues 
NHL is  80  times more  frequent  among HIV  positive  patients  worldwide  than in  the  general  
population.  About  4% of  symptomatic  HIV  positive  patients  develop  a  NHL each  year  [36]. 
Epstein-Barr virus (EBV) can be detected within about 40% of NHL patients with AIDS [29]. 
EBV is associated with HL and NHL, specially Burkitt's lymphoma in endemic areas. HL and NHL 
other than Burkitt's lymphoma are associated with EBV and immunosuppression [36].
Hepatitis  C  virus  (HCV)  and  human herpes  virus  8  (HHV 8)  have  also  been  linked  to  the 
development of NHL [36]. 
Helicobacter pylori is a confirmed risk factor for gastric NHL, namely MALT lymphoma [36].
Finally  human T-cell  lymphotropic  virus type 1  (HTLV-1),  endemic in  southern Japan,  in  the 
Caribbean and in Africa, causes a rare type of T-cell-leukaemia [36].
3.3.5  Therapy and tumours of haematopoietic and lymphoid tissues 
In comparison with other malignancies, some evidence suggests that the risk of NHL and HL is 
not considerably increased by exposure to ionizing radiation [32]. On the opposite, high levels of 
radiation increases the risk of  acute leukaemia. Indeed people exposed to the atomic bomb 
explosions in Japan had higher rates of myeloid leukaemias [34].
Exposure  to  alkylating  agents  (melphalan  and  nitrogen  mustard)  and  type  II topoisomerase 
inhibitors  (etoposide  and  teniposide)  during  chemotherapy  has  been  implicated  in  the 
development of myeloid leukaemia [32].
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3.4  Conceptual scheme of associated cancers in patients with tumours of 
haematopoietic and lymphoid tissues 
Figure 1: Conceptual scheme of associated cancers and tumours of haematopoietic and  
lymphoid tissues
Figure 1 shows the conceptual scheme of associated cancers and tumours of haematopoietic 
and lymphoid tissues. Common genetic and environmental factors can induce two concomitant 
cancers, but also an associated cancer before or after a tumour of haematopoietic and lymphoid 
tissue. Furthermore haematopoietic and lymphoid neoplasms and their therapies can result in 
immunosuppression,  which  can  secondarily  be  more  permissive  for  an  associated  cancer. 
Therapy alone can also directly induce the development of an associated cancer. 
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3.5  Secondary  cancers  in  the  population  of  lymphoid  and  haematopoietic  cancer 
patients in the literature 
3.5.1  Secondary cancer after a first malignant neoplasm 
Many studies have analysed the general risk of developing a  secondary malignant neoplasm 
(SMN) after a first malignant neoplasm [39][40][41]. 
The  cumulative  risk  of  developing  a  second  cancer  after  a  first  malignant  neoplasm varies 
between 2.6% and 5% after 20 years of follow-up [39][40][41].
High  rates  of  secondary  cancer  have  been  observed  among patients  with  an  initial  tumour 
diagnosis of retinoblastoma or malignant lymphoma (mostly HL). Several other types of tumours 
like leukaemia, soft-tissue sarcoma and Wilms’ tumour showed likewise an increased risk of 
developing a SMN [39][40][41].
Because of the high incidence of SMN observed after malignant lymphomas in these seminal  
studies  [39][40][41],  many  subsequent  studies  analysed  the  particular  risk  of  developing  a 
secondary cancer after a special subtype of lymphoid and haematopoietic cancers  [1]-[22][42]
[43].
3.5.2  Secondary neoplasm after lymphoid and haematopoietic cancer 
3.5.2.1  Secondary cancer after Hodgkin lymphoma 
Table  2 summarises  the  major  studies  on  secondary  cancers  after  HL  [1]-[9].  The  risk  of 
secondary neoplasms after HL has been widely investigated. The actuarial risk of developing a 
SMN varies between 10% after 20 years [1] and 27% after 25 years of follow-up [9].
Relative risks (RR) of SMN with the exception of non melanomatous skin cancers after HL vary 
between 2.3 (95% CI 2.2-2.49) [3] and 18.5 (95% CI 15.6-21.7) [1]. The increased RR of acute 
leukaemia varies between 9.9  [2] and 174.8  [1].  RR of  cancers of  thyroid,  lung,  breast  and 
gastrointestinal tract vary between 3.1-36.4, 2.6-27.3, 1.4-56.7 and 1.7-36.4 [1]-[9]. Leukaemias 
generally appeared during the first five years following HL. Solid cancers occurred mostly later,  
around 10-15 years after HL. Generally the risk of developing a SMN is higher when HL has 
been diagnosed at a young age. The risk of SMN increased likewise with the time of follow-up 
[1]-[9].
The influence of the type of therapy has been controversial. Chemotherapy tended to favour the 
occurrence of leukaemia. Radiotherapy seemed to influence the appearance of solid cancers like 
thyroid and breast cancers. Mixed therapy or salvage therapy tended to increase the risk of both  
solid and non solid SMN [1]-[9].
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Table 2: Main studies on secondary cancers after HL [1]-[9].
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3.5.2.2  Secondary cancer after non Hodgkin lymphoma 
Unlike HL, there is still little information in the literature on secondary cancers in patients with 
NHL due to the heterogeneity of tumour histotype and variable treatment. 
Cumulative incidence of any SMN after NHL has been 2.5% (95% CI 1.04-3.96) within 30 years 
from diagnosis of NHL in the study of Maule et al. [15]. Increased standardized incidence ratios 
(SIR) of secondary cancers in 2'563 NHL survivors have been 40.4 for thyroid cancers (six 
cases, 95% CI 14.8-88.0) and 6.97 for brain cancer (four cases, 95% CI 1.90-17.9) [15]. A 
second study [16] analysed the risk of SMN in 2'456 NHL patients and found 123 SMN. RR have 
been significantly elevated for all secondary cancers (RR 1.3; 95% CI 1.1-1.6), leukaemia (RR 
8.8; 95% CI 5.1-14.1) and lung cancer (RR 1.6; 95% CI 1.1-2.3) [16]. Secondary bladder cancers 
have been reported with an increased incidence in cyclophosphamide treated NHL patients [17]. 
3.5.2.3  Secondary cancer after hairy cell leukaemia 
Findings of the main studies on secondary cancers after hairy cell leukaemias (HCL) have been 
variable [10][11][12]. Some studies showed that patients with HCL did not have an increased risk 
of developing a SMN [11][12]. To the contrary, a recent study in 2007 estimated an actual risk of  
SMN of 31.9% at 25 years of follow up [13].
Increased  incidences  of  secondary  gastrointestinal,  lung,  thyroid  and  prostate  cancers  have 
been observed [13][14]. Generally, risks of lymphoid cancers like HL, NHL and MM after HCL, 
tended to be increased, but not all data showed a statistical significance [13][14]. Especially high 
incidences of malignancy occurring before and during HCL, have been observed [13][14].
The development of SMN has been highest in the period up to 2 years after diagnosis of the first  
tumour [13][14]. The role of the therapy as causative agent in the development of SMN and in 
particular a study on the role of Interferon has been controversial [13][14].
3.5.2.4  Secondary cancer after other lymphoid and haematopoietic cancers 
(MALT lymphomas, MCL, CLL, ALL) 
In the literature, other studies analysed the risk of secondary malignancies following mantle cell  
lymphomas (MCL) [42] and MALT lymphomas [43]. There was no clear statistical evidence that 
solid  cancers  occurred  more  frequently  after  these  specific  tumours  of  haematopoietic  and 
lymphoid  tissues  [42][43]. Some  studies  found  significant  increases  in  the  incidence  of 
melanoma and brain and lung cancers among CLL patients [18][19]. The incidence of secondary 
cancers after diagnosis of childhood ALL remains low [20][22] except for children diagnosed at 
the age of five or younger and those that received radiation. These children are at higher risk 
especially for secondary tumours arising in the central nervous system [21] .
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3.6  Hypothesis: tumours sharing same etiological factors should be associated 
Most  of  the  above  mentioned  studies  [1]-[22][42][43] investigated  the  incidence  of  cancers 
subsequent to the diagnosis of lymphoid and haematopoietic cancers. The inverse, studying the 
incidence of lymphoid and haematological tumours after a diagnosis of solid cancers has rarely 
been performed  [23]. Therefore we undertook this study to analyse the incidence of cancers 
which occurred before the diagnosis of lymphoid and haematological tumours.
We analysed the data set on haematopoietic stem cell diseases and lymphoid cancers and their  
associated cancers from the cancer registry of the Canton of Zurich including data from January 
1980 to June 2008. We expected that associated tumours would share similar etiological factors, 
be they known or hitherto unknown.
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4  Materials and methods 
4.1  Cancer registry of the Canton of Zurich 
4.1.1  Purpose of cancer registry 
The cancer registry of the Canton of Zurich was founded in 1980 and collects all data on the  
incidence of malignant tumours among the residents of this Canton and serves as a basis for 
epidemiological and clinical research.
4.1.2  Covered population of the Canton of Zurich 
The  inhabitants  of  the  Canton  of  Zurich  account  for  approximately  one  sixth  of  the  Swiss 
population (17.2% in 2007, respectively 1'307'567 residents) [44][45].
4.2  Data sample 
4.2.1  Origin of data sample 
Death certificates from the Federal Office for Statistics and histology, cytology or autopsy reports 
as  well  as  clinical  summaries  from  hospitals,  specialists  and  general  medicine  physicians, 
constitute the available sources of the cancer registry [44].
4.2.2  Old cases and cases diagnosed outside the Canton of Zurich 
Older cases (older than 1980) and cases diagnosed outside the Canton of Zurich, have been 
added from clinical files as well as from other Swiss cancer registries [44].
4.2.3  Characteristics of the data 
Table 3: Characteristics of the data collected from the cancer registry of the Canton of Zurich
Table 3 shows two examples of the characteristics of the data collected from the cancer registry 
of  the Canton of  Zurich.  Each patient  has a unique identification number (pat_id)  and each 
tumour has been separately recorded (fall_id). Gender (s), birth date (geb_dt) and if applicable 
year of death (tod_dt), have been registered for every patient. Dates of the diagnosis of tumours  
of haematopoietic and lymphoid tissues and associated tumours have been extracted. 
The dates of the morphologic diagnosis of tumours (month and year of dx_morph) were used to 
calculate the age at diagnosis and to calculate the interval between  two or more  associated 
cancers. When these data were missing, dates of the clinical diagnosis (dx_klin) or the incidence 
year (month of june and inz_jahr) were used. To determine when the associated cancer was 
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preceding or following the tumour of haematopoietic and lymphoid tissues, the difference of age 
at their diagnoses was calculated. In the case of simultaneous cancers (example 1 of Table 3) 
the associated cancer was considered as preceding the tumour of haematopoietic and lymphoid 
tissues.
4.3  Inclusion  criteria  and  attributions  of  ICD-O-1  and-3  codes  for  tumours  of 
haematopoietic and lymphoid tissues 
4.3.1  Inclusion criteria 
We extracted our data sample from files of the Canton of Zurich cancer registry by searching for 
ICD-O-1 and-3 codes of tumours of haematopoietic and lymphoid tissues based on the WHO 
classification.
4.3.2  Attribution  of  ICD-O-1  and-3  codes  for  tumours  of  haematopoietic  and 
lymphoid tissues 
Table  4 shows  the  attribution  of  ICD-O-1  and-3  codes  for  tumours  of  haematopoietic  and 
lymphoid tissues  [30].  Tumours were  grouped according  to  their  common histological  origin: 
indolent B cell lymphoma, aggressive B cell lymphoma, T cell lymphoma, haematopoietic stem 
cell disease (HPSCD including ALL, AML, CML and MDS), MM and HL. The ICD-O-1 code was 
used in the cancer registry of the Canton of Zurich cancer until 2003, it then was replaced by  
ICD-O-3 code. For analyses ICD-O-1 codes were converted into ICD-O-3 codes [30].
4.3.3  Selection of eight groups of tumours 
Eight  tumour  groups were  finally  selected for  further  analyses due to  their  high  incidences: 
diffuse large B cell lymphoma (DLBL), lymphoplasmacytic lymphoma (LPL), MCL, MM, CLL, HL, 
HPSCD and FL. 
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 Subtypes ICD-O-1 codes ICD-O-3 codes
97303, 97311, 98303 9732/3, 9731/3, 9733/3
97313 9734/3
 Indolent B cell lymphomas
 SLL, CLL 96203, 98233, 99701 9670/3,9823/3, 9960/3
 Mantle cell lymphoma 96223, 96773 9673/3
 Marginal zone lymphoma 97113 9699/3, 9689/3
96113, 97613 9671/3, 9761/3
96143 9676/3, 9675/3
 Follicular lymphoma 96903, 96923, 96973 9698/3 9691/3 9695/3, 9690/3
 Hairy cell leukaemia 99403 9940/3
98253 9832/3; 9833/3
 Aggressive B cell lymphomas
96123, 96323, 96403, 95913 9680/3, 9684/3, 9679/3, 9591/3
97503, 96003 9687/3, 9591/3
 T cell lymphomas 
97023, 97043, 98273
97003, 97013 9700/3, 9701/3
 AILT 97053, 97671 9705/3, 9767/1
97143 9714/3
97203, 97233 9755/3, 9755/3
 Hodgkin lymphomas
 MCHL 96523 9652/3
 LDHL 96533 9653/3
 NLPHL 96513, 96603 9651/3, 9659/3
 NSHL 96563, 96633 9665/3, 9663/3
 HL NOS 96503 9650/3
 HPSCD: ALL, AML, CML, MDS 
96303, 98213, 98003, 98013, 98203
 CML, MPD NOS
 MDS NOS 99890 9989/3, 9980/3, 9985/3
 Multiple myelomas
 Multiple myeloma 
 Extramedullary 
plasmocytoma
 LPL, Waldenström's 
disease
 Diffuse centroblastic 
centrocytic lymphoma
 Prolymphocytic 
lymphoma
 Diffuse large B cell 
lymphoma,NHL, 
lymphosarcoma NOS
 Burkitt lymphoma, 
Indeterminate NHL, non 
Burkitt lymphoma
 T cell lymphoma, T cell 
leukaemia
9709/3, 9717/3, 9719/3, 9702/3, 
9827/3, 9834/3
 Mycosis fungoides, 
Sézary syndrome
 Anaplastic large cell 
lymphoma
 HS, lymphohistiocytic 
lymphoma
 LBL, pre B lymphoma, 
ALL, ALL NOS
9728/3, 9729/3, 9727/3, 9835/3, 
9836/3, 9800/3, 9801/3, 9823/3
 AML M3/M4, AML M2/M5, 
AML NOS
98653, 98663, 98673, 98603, 98623, 
98903, 98923, 98403, 98413, 98613, 
98643, 98803, 98913, 99103, 98943, 
99891
9866/3, 9867/3, 9860/3, 9891/3, 
9840/3, 9861/3, 9860/3, 9891/3, 
9910/3, 9983/3, 9874/3
98633, 98423, 98683, 98933, 99203, 
99303, 99501, 99601, 99611, 99621
9863/3, 9963/3, 9950/3, 9945/3, 
9930/3, 9950/3, 9975/3, 9961/3, 
9962/3
Table 4: Attribution of ICD-O-1 and-3 codes for tumours of haematopoietic and 
lymphoid tissues [30] 
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4.4  Exclusion criteria 
 ICD-O-1
Malignant lymphoma NOS 95903
97223
97413
97651
98033
98223
98243
99323
99903
 Names of excluded ICD-O-1 codes
Malignant 
lymphoma not 
other specified 
(NOS)  
Miscellaneous 
myeloid diseases
Letterer-Siwe's disease, acute differentiated 
progressive histiocytosis, acute progressive 
histiocytosis, acute reticulosis of infancy, acute 
infantile reticuloendotheliosis, non-lipid 
reticuloendotheliosis 
Malignant mastocytosis, systemic tissue mast cell 
disease
Monoclonal gammopathy
Leukaemias NOS
Subacute lymphoid leukaemia, subacute 
lymphocytic leukaemia, subacute lymphatic 
leukaemia
Aleukemic lymphoid leukaemia, aleukemic 
lymphocytic leukaemia, aleukemic lymphatic 
leukaemia
Acute myelofibrosis
No microscopic confirmation, clinically malignant  
tumour
Table 5: Excluded ICD-O-1 codes
All benign neoplasms which  have not been registered systematically, were excluded. ICD-O-1 
codes  listed  in  Table  5 were  also  excluded  because  of  their  rarity  and  lack  of  specificity. 
Furthermore 31 patients of a total of 12'829 were eliminated because of unknown dates of the 
diagnosis of lymphohaematopoietic cancer. 
4.5  Associated  malignant  neoplasms:  the  definition, ICD-9  and-10  codes and 
incidence rates 
4.5.1  Definition of associated malignant neoplasms 
All  diagnoses in  addition to  a  tumour  of  haematopoietic  and lymphoid  tissues that  occurred 
during a patient's lifetime were registered as associated malignant neoplasms (AMN).
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4.5.2  Attribution of ICD-10 codes for associated malignancies 
ICD-9 and-10 codes were used to describe the associated cancer. ICD-9 code was used in the 
cancer registry of the Canton of Zurich until 2003, it then was replaced by ICD-10 code. ICD-9 
codes were converted into ICD-10 codes (conversion's table [46]).
 Names  Names
Cancer of head and neck C56 Cancer of ovary
C15 
C16 Cancer of stomach C61 Cancer of prostate
C18 Cancer of colon C62 Cancer of testis
C19-21 Cancer of rectum and anus C60, C63
C22 C67 Cancer of bladder
C25 Cancer of pancreas C64, C65 Cancer of kidney and renal pelvis
C66, C68 Cancer of other urinary organs
C34 Cancer of bronchus and lung
C81 Hodgkin lymphoma
Non-Hodgkin lymphoma
C43 Melanoma of skin C90-95 Leukaemia
C44, C46 C88-C90
C50 Cancer of breast
C54, C55 Cancer of uterus C77-C79 Secondary malignancy
C53 Cancer of cervix C80, C97
ICD-10 
codes
ICD-10 
codes
C00-C14, 
C30-C32, 
C46, C76
Cancer of esophagus C51, C52, C57, C58
Cancer of other female genital 
organs
Cancer of other male genital 
organs
Cancer of liver and intrahepatic 
bile duct
C17, C23, 
C24, C26, 
C45, C48
Cancer of other gastrointestinal 
organs and peritoneum
C47, C70-
C72
Cancer of brain and nervous 
system
C33, C38, 
C39, C45
Other respiratory and intrathoracic 
cancer
C40, C41, 
C46, C47, 
C49
Cancer of bone and connective 
tissue
C46, C82-85, 
C96  
Other non-epithelial cancer of 
skin Multiple myeloma
C37, C38, 
C45, C46, 
C69, C74-
C76, C96
Other and unspecified primary 
cancer
Malignant neoplasm without 
specification of site
Table 6: Attribution of ICD-10 for codes for associated malignancies 
Table 6 shows the ICD-10 codes used in our study. AMN were categorised in two main groups: 
non solid and solid tumours.
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4.5.3  Incidence rates of associated malignant neoplasms 
4.5.3.1  Incidence  rates  representing  the  ratio  of  numbers  of  AMN  to  numbers  of 
tumours in selected tumour groups 
4.5.3.1.1  Method 
To assess the incidence of associated neoplasms among the eight  most  frequent  groups of 
tumours (DLBL, CLL, HL, LPL, MCL, MM, FL and HPSCD), we calculated the incidence rates as 
the ratio of numbers of AMN and numbers of cancers of haematopoietic and lymphoid tissues in 
each group. 
4.5.3.1.2  Numbers of solid AMN 
Figure 2: Numbers of solid AMN in different encountered situations: AMN before the 
diagnosis of the tumour of haematopoietic and lymphoid tissues (on the left side) and AMN  
after the diagnosis of the tumour of haematopoietic and lymphoid tissues (on the right side)
To  simplify  the  calculation  of  the  incidence  rates  of  AMN  and  to  avoid  including  cases  of 
lymphoma progression and recurrence, we focused our analyses on solid AMN. Figure 2 shows 
different variations of associated cancers with their attributed numbers of solid AMN according to 
cancer associations.
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4.5.3.1.3  Age-, date- and gender-specific incidence rates 
Incidence rates were analysed for all types of associated malignant neoplasms and grouped into 
age categories according to the age at diagnosis (5 year age groups) as well as calendar periods 
of  haematopoietic  and  lymphoid  neoplasm  registration  (<1988,  1989-1997  and  >1998).  All  
incidence rate curves were calculated for  both genders (M and F)  and separately  (M or F).  
Incidence rate curves were obtained with rolling averages over two 5 year age groups.
4.5.3.1.4  Incidence rates among three groups of solid AMN 
Figure 3: Three groups of AMN: AMN before and after haematopoietic and lymphoid  
neoplasm (top), previous AMN and AMN in the interval of one year after the  
lymphohaematopoietic cancer diagnosis (middle) and AMN before the lymphohaematopoietic  
cancer diagnosis (bottom) 
Initially incidence rates were calculated for all solid AMN before and after haematopoietic and 
lymphoid neoplasm. To reduce the influence of the survival rate of the tumour of haematopoietic  
and lymphoid tissues on the occurrence of a second associated cancer, we selected two other  
groups of solid AMN illustrated in Figure 3: 
● AMN which occurred only before the lymphohaematopoietic cancer diagnosis 
● AMN  which  occurred  before  the  lymphohaematopoietic  cancer  diagnosis  and  in  the 
interval of one year afterwards. 
24
Cancer of haematopoietic and 
lymphoid tissues
Lifetime (years)0 1Previous AMN Subsequent AMN
AMN (before and after)
AMN (before and one year after)
AMN (before)
4.5.3.2  Statistical  analyses  for  expected  number  of  associated  cancers  using  a 
generalized additive model for Poisson regression 
4.5.3.2.1  Method 
For statistical purposes a generalized additive model (GAM) for Poisson regression has been 
used in cooperation with Dr. Kaspar Rufibach from the Biostatistics Unit of the Institute of Social 
and Preventive Medecine of the University of Zurich. AMN rates were calculated as events per 
time unit of age group of diagnosis of lymphohaematopoietic cancer. Patients were censored at 
the date of death. When this data was missing patients were censored at the date where the last 
incidence year of cancer was recorded.
Computations were performed using R, where GAM’s were generated via the R-package mgcv 
[47]. 
4.5.3.2.2  Excluded AMN in calculation of the expected number of AMN 
Figure 4: Excluded patients with more than one cancer of  haematopoietic and lymphoid tissues:  
patients with AMN before tumour of haematopoietic and lymphoid tissues (left) and AMN after  
tumour of haematopoietic and lymphoid tissues (right)
Figure  4 shows  different  encountered  situations  of  associated  cancers.  To  calculate  the 
estimated number of  AMN and to  avoid  also  including  cases of  lymphoma progression and 
recurrence, patients with more than one  cancer of haematopoietic and lymphoid tissues were 
excluded.
4.5.3.2.3  Age-and gender-specific expected numbers of AMN 
Age-and  gender-specific estimated  numbers  of  AMN  were  calculated  for  seven  groups  of 
tumours  (DLBL,  CLL,  HL,  LPL,  FL,  MM and  HPSCD).  Gender  and  group  of  tumours  were 
entered as nominal variables and the age as a continuous variable. Age was grouped into five  
year intervals starting at 0. Expected numbers of AMN were studied in the two groups of AMN: all  
AMN  before  and  after  haematopoietic  and  lymphoid  neoplasm  and  AMN  before 
lymphohaematopoietic cancer.
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5  Results 
5.1  Numbers of patients, tumours of haematopoietic and lymphoid tissues and AMN 
5.1.1  Numbers of patients and tumours of haematopoietic and lymphoid tissues 
A total of 12'798 patients with one or more than one cancer of haematopoietic and lymphoid 
tissues were identified. After excluding all patients with more than one tumour of haematopoietic 
and lymphoid tissues, 10'923 patients were identified. 
Some patients had multiple tumours of haematopoietic and lymphoid tissues, therefore the total  
number of tumours of haematopoietic and lymphoid tissues was higher and added up to 12'994 
tumours.
5.1.2  Numbers of associated malignant neoplasms 
Table 8 shows the number of every type of solid and non solid AMN among the main groups of 
tumours of haematopoietic and lymphoid tissues. In total we detected 2'885 previous and 
subsequent AMN in 12'798 patients (439 non solid AMN and 2'446 solid AMN). The most 
frequent solid AMN are cancers of prostate (433 cases), cancers of breast (354 cases), cancers 
of lung (227 cases), cancers of colorectum (295 cases). After excluding patients with more than 
one cancer of haematopoietic and lymphoid tissues, we detected 2'374 previous and subsequent 
AMN in 10'923 patients. 
5.1.3  Number of AMN per patient 
Among 12'798 patients  with  one or  more  than one  cancer of  haematopoietic  and lymphoid 
tissues, 2'061 patients had one associated malignant neoplasm and 313 patients had more than 
one AMN.
Numbers of patients sex ratio
total men women men/women
0 10424 5513 4911 1.12
1 2061 1183 878 1.35
 >1 313 193 120 1.61
2 273 168 105 1.6
3 34 23 11 2.09
4 5 2 3 0.67
5 1 0 1 0
Number of AMN per 
patient
Table 7: Numbers of AMN per patient, numbers of patients and sex ratios
Table 7 shows the number of patients with 0, 1 and more than 1 AMN and their sex ratios. There 
was a male predominance in most of the groups of patients with one or more than one AMN. 
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Table 8: Numbers of AMN in patients with one or more than one tumour of haematopoietic and 
lymphoid tissues
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Numbers of AMN HL HPSCD MM Total
1011 3125 2107 1902 4108 505 12758
    AMN 266 652 417 347 1076 127 2885
Non solid   AMN   57 171 55 37 98 21 439
Leukemias   15 95 20 18 42 11 201
Non-Hodgkin  lymphoma   37 47 7 16 26 5 138
4 18 8 2 16 3 51
Hodgkin lymphoma 1 11 20 1 14 2 49
Solid   AMN   209 481 362 310 978 106 2446
Cancer of bladder   10 37 23 28 58 7 163
Cancer of bone and connective tissue   4 4 7 2 12 5 34
Cancer of brain and nervous system   0 2 1 1 13 1 18
Cancer of breast   45 47 45 48 158 11 354
Cancer of bronchus, lung   42 32 28 23 90 12 227
Cancer of cervix   1 9 5 2 12 2 31
Cancer of colon   12 48 21 28 71 4 184
Cancer of esophagus   6 5 2 4 3 0 20
Cancer of head and neck   12 11 14 5 37 3 82
Cancer of kidney and renal pelvis   0 0 0 0 0 0 0
5 3 7 3 8 2 28
Cancer of other female genital organs   4 12 5 9 21 2 53
Cancer of other GI organs, peritoneum   1 5 2 4 19 0 31
Cancer of other male genital organs   0 1 1 1 0 3 6
Cancer of other urinary organs   6 17 13 9 22 1 68
Cancer of ovary   0 0 0 0 0 0 0
Cancer of pancreas   6 7 5 5 17 1 41
Cancer of prostate   14 102 69 61 164 23 433
Cancer of rectum and anus   6 31 15 17 40 2 111
Cancer of stomach   3 13 14 8 39 0 77
Cancer of testis   0 10 3 2 3 2 20
Cancer of thyroid   5 11 7 7 17 2 49
Cancer of uterus   2 20 12 15 36 1 86
Melanoma of skin   12 29 26 13 64 7 151
Other non-epithelial cancer of skin   8 18 36 12 66 15 155
14 12 4 6 24 0 60
Aggressive 
B cell 
lymphomas
Indolent B 
cell 
lymphomas
T cell 
lymphomas
Tumours of haematopoietic and 
lymphoid tissues
Multiple myeloma   
Cancer of liver and intrahepatic bile duct   
Malignant neoplasm without specification 
of site and other respiratory and 
intrathoracic cancer
5.2  Characteristics of patients with AMN: a comparison of two populations 
5.2.1  Average age and sex ratio of patients with AMN 
5.2.1.1  Average age 
As  a  reference  group  we  chose  to  compare  the  characteristics  of  patients  with  AMN  with 
characteristics of all patients with one or more tumours of haematopoietic and lymphoid tissues.
Average age at diagnosis of haematopoietic and lymphoid cancer among patients with AMN is 68 
years. In comparison the average age at diagnosis of all patients with tumours of haematopoietic  
and lymphoid tissues is 63. 
Figure 5: Average age of groups of tumours of haematopoietic and lymphoid tissues among  
men and women in the two populations: patients with tumours of haematopoietic and  
lymphoid tissues and patients with AMN
Figure  5 shows  the  average  age  at  time  of  diagnosis  of  the  main  groups  of  tumours  of  
haematopoietic and lymphoid tissues among women and men.
Among women, the average age at diagnosis of haematopoietic and lymphoid cancer is slightly 
higher in the two groups of populations.
5.2.1.2  Sex ratio 
Sex ratios show a male predominance with an average of 1.3 in the group of AMN and of 1.2 in  
all patients. 
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5.2.2  Numbers  of  AMN  per  thousand  tumours  of  haematopoietic  and  lymphoid 
tissues in patients with AMN 
Table 9 describes the numbers of AMN per thousand lymphohaematopoietic tumours, sex ratios 
and  age  averages  for  every  group  of  cancer  in  all  patients  with  one  or  more  tumours  of  
haematopoietic and lymphoid tissues (first column) and in patients with AMN (second column). 
Patients  with  AMN include  patients  with  solid  and  non  solid  AMN as  well  as  previous  and 
subsequent AMN.
An average of 205 in 1'000 lymphohaematopoetic cancers are associated with another cancer.  
AMN  are  most  frequently  associated  with  indolent  B  cell  lymphomas  as  well  as  Hodgkin 
lymphomas (237cases/1'000 for both).
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Table 9: Numbers of AMN per thousand tumours of haematopoietic and lymphoid tissues in all  
patients with one or more than one tumour of haematopoietic and lymphoid tissues and patients  
with AMN
30
Patients with associated malignant neoplasms
Characteristics
Numbers of AMN
Sex ratios
Numbers of AMN
Sex ratios
M and F F M M and F F  M 
12994 5997 6997 1.2 63 2662 1142 1520 1.3 68 205
1933 924 1009 1.1 69.7 333 159 174 1.1 72.9 172
1896 909 987 1.1 69.8 321 155 166 1.1 73 169
37 15 22 1.5 65.6 12 4 8 2 70.8 324
Indolent B cell lymphomas 4190 1964 2226 1.1 67.4 991 434 557 1.3 69.4 237
SLL, CLL 2091 933 1158 1.2 70.1 545 221 324 1.5 71.4 261
Mantle cell lymphoma 267 92 175 1.9 67.4 55 16 39 2.4 69.1 206
Marginal zone lymphoma 293 173 120 0.7 64.6 76 46 30 0.7 70.2 259
482 224 258 1.2 68.8 119 59 60 1 68.5 247
321 178 143 0.8 65.4 66 35 31 0.9 65.1 206
Follicular lymphoma 566 321 245 0.8 61 93 47 46 1 63.7 164
154 37 117 3.2 58.6 33 8 25 3.1 63.9 214
16 6 10 1.7 68.6 4 2 2 1 67.8 250
Aggressive B cell lymphomas 2147 997 1150 1.2 62.6 383 159 224 1.4 69.2 178
2018 954 1064 1.1 63.6 369 154 215 1.4 69.6 183
129 43 86 2 47 14 5 9 1.8 57.7 109
T cell lymphomas 515 220 295 1.3 62.3 112 37 75 2 68.2 217
202 98 104 1.1 62.1 33 13 20 1.5 66.7 163
134 50 84 1.7 65.4 36 8 28 3.5 67.8 269
AILT 48 25 23 0.9 68.4 13 7 6 0.9 76.7 271
110 40 70 1.8 57.2 22 6 16 2.7 65 200
21 7 14 2 56.4 8 3 5 1.7 70.4 381
Hodgkin lymphomas 1015 441 574 1.3 41.3 241 110 131 1.2 47.5 237
MCHL 198 74 124 1.7 45.8 37 17 20 1.2 57 187
LDHL 33 10 23 2.3 59.6 10 2 8 4 70.9 303
NLPHL 78 21 57 2.7 41.8 19 4 15 3.8 54.6 244
NSHL 526 250 276 1.1 37.9 63 30 33 1.1 51.6 120
HL NOS 180 86 94 1.1 42.9 112 57 55 1 38.9 622
3194 1451 1743 1.2 60 602 243 359 1.5 69.8 188
494 212 282 1.3 33.7 40 18 22 1.2 63.4 81
1344 624 720 1.2 64.2 257 113 144 1.3 70 191
CML MPD NOS 850 399 451 1.1 64.1 171 64 107 1.7 68.1 201
MDS NOS 506 216 290 1.3 67.6 134 48 86 1.8 73.3 265
All patients with tumours of haematopoietic and 
lymphoid tissues 
Age 
averages 
Age 
averages 
Per 
thousand 
All tumours of haematopoietic 
and lymphoid tissues
Multiple myelomas
Multiple myeloma
Extramedullary plasmocytoma
LPL Waldenstrom disease
Diffuse centroblastic 
centrocytic lymphoma
Hairy cell leukaemia
Prolymphocytic lymphoma
Diffuse large B cell lymphoma, 
NHL, lymphosarcoma NOS
Burkitt lymphoma, 
Indeterminate NHL , non 
Burkitt NHL
T cell lymphoma, T cell 
leukamia
Mycosis fungoides, Sezary 
syndrome
Anaplastic large cell 
lymphoma
HS, lymphohistiocytic 
lymphoma
HPSCD (ALL, AML, CML, 
MDS)
LBL, Pre B cell lymphoma, 
ALL, Acute lymphatic 
leukaemia NOS
AML M3/M4, AML M2/M5, 
AML NOS
5.3  Illustrations of lymphohaematopoietic cancers and their  associated malignancies 
with scatter diagrams 
5.3.1  Lymphohaematopoietic cancers and their associated solid malignancies 
All tumours of haematopoietic and lymphoid tissues and solid AMN
Figure 6: Scatter diagram: all lymphohaematopoietic cancers and their associated solid 
malignancies
Figure 6 shows the scatter diagram of lymphohaematopoietic cancers and their associated solid 
malignancies. The x-axis shows the time interval in years between the tumour of haematopoietic 
and lymphoid tissues and the associated cancer.  The y-axis  shows the age at  diagnosis  of  
lymphohaematopoietic  cancer  in  years.  Furthermore  calendar  years  at  diagnosis  of  the 
lymphohaematopoietic cancer are indicated with different symbols (in the legend). The orange 
rectangle defines the interval of 10 years before and after lymphohaematopoietic cancers. Cases 
of  AMN which have been diagnosed before or  at  the  age of  50  are  represented below the 
diagonal black line.
The scatter diagram describes a trapezoid figure. Diagnoses of lymphohaematopoietic cancers 
in young people (most of all in the 1980's) are followed by subsequent AMN (right part of the  
scatter diagram). In contrast a predominance of previous AMN was observed among the oldest 
population (left part of the scatter diagram).  Most of AMN occur within the interval of 10 years 
before and after lymphohaematopoietic cancers diagnosed between 50 and 90 years.
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5.3.2  DLBL,  CLL,  HL,  LPL,  MCL,  MM,  HPSCD,  FL  and  their  associated  solid 
malignancies 
Figure 7 to 14 show scatter diagrams of a subtype of lymphohaematopoietic cancers and their  
associated malignancies. The x-axis shows the time interval between the subtype of tumour of  
haematopoietic and lymphoid tissues and the associated solid cancer in years. The y-axis shows 
the  age at  diagnosis  of  the  subtype of  lymphohaematopoietic  cancer  in  years.  Furthermore 
calendar  years at  diagnosis  of  the lymphohaematopoietic  cancer  are indicated with  different  
symbols (in the legend). The orange rectangle defines the interval of 10 years before and after 
the  subtype  of  lymphohaematopoietic  cancers.  Cases  of  AMN which  have  been  diagnosed 
before or at the age of 50 are represented below the diagonal black line. The right side of the 
figure 7 to 14 shows the exact numbers of lymphohaematopoietic cancers , numbers of solid 
AMN and incidence rates of solid AMN.
Figure 7 to 14 show that most of the solid AMN occur within the interval of 10 years before and 
after DLBL, FL, MCL, LPL and CLL. AMN occur mainly after HL was diagnosed in childhood. 
AMN appear mainly before HPSCD diagnosed in an older population. 
HL and HPSCD have the highest rate of associated malignancies before the age of 50 (cases 
represented below the black line). 
The scatter diagram of HL illustrates less AMN in comparison with the scatter diagrams of MM, 
DLBL, CLL and HPSCD. But the exact data in the tables shows an higher incidence rate of solid 
AMN in HL patients.
Age range
0-4 1 0 0
5-9 9 2 0.22
10-14 30 1 0.03
15-19 67 9 0.13
20-24 125 19 0.15
25-29 107 19 0.18
30-34 120 25 0.21
35-39 90 14 0.16
40-44 99 17 0.17
45-49 47 12 0.26
50-54 55 11 0.2
55-59 50 16 0.32
60-64 42 14 0.33
65-69 58 22 0.38
70-74 37 12 0.32
75-79 39 9 0.23
80-84 20 2 0.1
Number of 
lymphohaemato
poietic cancers 
Number of 
solid AMN
Incidence 
rate of solid 
AMN    
HL before and after solid AMN
Figure 7: Scatter diagram: HL and their associated solid malignancies
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Age range
0-4 0 0 /
5-9 0 0 /
10-14 0 0 /
15-19 1 0 0
20-24 2 0 0
25-29 3 0 0
30-34 8 0 0
35-39 22 2 0.09
40-44 31 2 0.06
45-49 44 6 0.14
50-54 78 6 0.08
55-59 77 19 0.25
60-64 67 17 0.25
65-69 70 19 0.27
70-74 57 6 0.11
75-79 49 14 0.29
80-84 35 4 0.11
Number of 
lymphohaemato
poietic cancers 
Number of 
solid AMN
Incidence 
rate of solid 
AMN    
FL before and after solid AMN
Figure 8: Scatter diagram: FL and their associated solid malignancies
Figure 9: Scatter diagram: MM and their associated solid malignancies
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Age range
0-4 0 0 /
5-9 0 0 /
10-14 0 0 /
15-19 1 0 0
20-24 0 0 /
25-29 1 0 0
30-34 2 0 0
35-39 17 0 0
40-44 45 1 0.02
45-49 64 4 0.06
50-54 91 10 0.11
55-59 163 14 0.09
60-64 194 30 0.15
65-69 278 35 0.13
70-74 326 73 0.22
75-79 320 60 0.19
80-84 266 52 0.20
Number of 
lymphohaemat
opoietic 
cancers 
Number of 
solid AMN
Incidence 
rate of solid 
AMN    
MM before and after solid AMN
Figure 10: Scatter diagram: LPL and their associated solid malignancies
Figure 11: Scatter diagram: DLBL and their associated solid malignancies
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Age range
0-4 0 0 /
5-9 0 0 /
10-14 1 0 0
15-19 0 0 /
20-24 0 0 /
25-29 2 0 0
30-34 3 0 0
35-39 3 0 0
40-44 11 2 0.18
45-49 18 3 0.17
50-54 31 3 0.10
55-59 51 12 0.24
60-64 39 11 0.28
65-69 66 25 0.38
70-74 75 18 0.24
75-79 71 17 0.24
80-84 69 11 0.16
Number of 
lymphohaemato
poietic cancers 
Number of 
solid AMN
Incidence 
rate of solid 
AMN    
LPL before and after solid AMN
Age range
0-4 2 0 0
5-9 12 0 0
10-14 4 0 0
15-19 23 1 0.04
20-24 24 0 0
25-29 48 1 0.02
30-34 67 5 0.07
35-39 78 8 0.10
40-44 78 11 0.14
45-49 94 6 0.06
50-54 120 14 0.12
55-59 161 20 0.12
60-64 178 30 0.17
65-69 184 46 0.25
70-74 256 53 0.21
75-79 276 67 0.24
80-84 242 54 0.22
Number of 
lymphohaemato
poietic cancers 
Number of 
solid AMN
Incidence 
rate of solid 
AMN    
DLBL before and after solid AMN
Age range
0-4 0 0 /
5-9 0 0 /
10-14 0 0 /
15-19 3 0 0
20-24 2 0 0
25-29 6 0 0
30-34 5 0 0
35-39 23 3 0.13
40-44 31 5 0.16
45-49 53 10 0.19
50-54 108 17 0.16
55-59 168 32 0.19
60-64 242 77 0.32
65-69 271 75 0.28
70-74 325 101 0.31
75-79 354 102 0.29
80-84 264 64 0.24
Number  of 
lymphohaemato
poietic cancers 
Number of 
solid AMN
Incidence 
rate of 
solid AMN  
  
CLL before and after solid AMN
Figure 12: Scatter diagram: CLL and their associated solid malignancies
Age range
0-4 134 0 0
5-9 74 0 0
10-14 49 0 0
15-19 35 1 0.03
20-24 59 1 0.02
25-29 71 3 0.04
30-34 62 3 0.05
35-39 89 5 0.06
40-44 109 11 0.10
45-49 114 14 0.12
50-54 144 14 0.10
55-59 184 27 0.15
60-64 239 36 0.15
65-69 314 64 0.20
70-74 430 94 0.22
75-79 463 88 0.19
80-84 354 79 0.22
Number of 
lymphohaemat
opoietic 
cancers 
Number of 
solid AMN
Incidence 
rate of 
solid AMN  
  
HPSCD before and after solid AMN
Figure 13: Scatter diagram: HPSCD and their associated solid malignancies
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Age range
0-4 0 0 /
5-9 0 0 /
10-14 0 0 /
15-19 0 0 /
20-24 0 0 /
25-29 1 0 0
30-34 3 0 0
35-39 5 0 0
40-44 6 0 0
45-49 6 1 0.17
50-54 16 0 0
55-59 24 4 0.17
60-64 35 8 0.23
65-69 52 13 0.25
70-74 34 10 0.29
75-79 39 8 0.21
80-84 34 7 0.21
Number of 
lymphohaemat
opoietic 
cancers 
Number 
of solid 
AMN
Incidence 
rate of 
solid AMN  
  
MCL before and after solid AMN
Figure 14: Scatter diagram: MCL and their associated solid malignancies
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5.4  Incidence rates of associated malignant neoplasms 
5.4.1  Incidence  rates  representing  the  ratio  of  numbers  of  AMN  to  numbers  of 
tumours in selected groups of tumours 
5.4.1.1  Age-and  gender-specific  incidence  rates  of  associated  solid  malignancies 
before and after tumour of haematopoietic and lymphoid tissues 
Figure 15 shows the incidence rate curves of associated solid malignancies before and after a 
subtype of tumour of haematopoietic and lymphoid tissues (MM, DLBL, HL, LPL, CLL, HPSCD, 
FL and MCL) among men and women and  each one  separately. The x-axis shows the age at 
diagnosis of lymphohaematopoietic cancer in 5 year intervall age groups (in years). The y-axis  
shows the incidence rate of solid AMN in each age group. 
There is a gradual increase of the incidence rate of solid AMN in each tumoral group with age at 
diagnosis. The highest incidence rate of AMN occurs among HL patients with a peak-incidence at  
65-74 year old.
A steeper increase in the incidence rate with age is observed among men while the increase is 
more gradual among women. 
5.4.1.2  Age-and  gender-specific  incidence  rates  of  associated  solid  malignancies 
before tumour of haematopoietic and lymphoid tissues 
Figure 16 shows the incidence rate curves of associated solid malignancies before tumour of 
haematopoietic and lymphoid tissues among men and women and each one separately. 
The gradual increase in age at diagnosis is still observed in these incidence rate curves. 
Contrary to other groups of tumours a peak-incidence rate of solid AMN among HL persists at 
70-74 year old (particularly among women). Among other groups of tumours of haematopoietic 
and lymphoid tissues only few differences of incidence rates are observed. 
5.4.1.3  Age-and  gender-specific  incidence  rates  of  associated  solid  malignancies 
before and 1 year after tumour of haematopoietic and lymphoid tissues 
Figure 17 shows the incidence rate curves of associated solid malignancies before and one year 
after tumour of haematopoietic and lymphoid tissues among men and women and each one 
separately. Few differences are observed between Figure 16 and Figure 17.
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Figure 15: Incidence rate curves of associated solid malignancies before and after tumour of 
haematopoietic and lymphoid tissues, men and women (top), men (middle), women (bottom)  
(x: age at diagnosis of  tumour of haematopoietic and lymphoid tissues, y: incidence rate of solid AMN)
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MEN AND WOMEN
MEN
WOMEN
Figure 16: Incidence rate curves of associated solid malignancies before tumour of  
haematopoietic and lymphoid tissues, men and women (top), men (middle), women (bottom)  
(x: age at diagnosis of tumour of haematopoietic and lymphoid tissues, y: incidence rate of solid AMN)
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MEN AND WOMEN
MEN
WOMEN
Figure 17: Incidence rate curves of associated solid malignancies before and 1 year after tumour 
of haematopoietic and lymphoid tissues, men and women (top), men (middle), women (bottom)  
(x: age at diagnosis of tumour of haematopoietic and lymphoid tissues, y: incidence rate of solid AMN)
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MEN AND WOMEN
MEN
WOMEN
5.4.2  Statistical  analyses  for  expected  numbers  of  associated  cancers  using  a 
generalized  additive  model  for  Poisson  regression  among  seven  selected  groups 
MM, CLL, LPL, FL, DLBL, HL, HPSCD 
Figure 18 shows the estimated mean numbers of AMN among women and men before tumour of 
haematopoietic and lymphoid tissues. The group specific analyses show the highest increase of 
estimated mean numbers of AMN in patients with HL in men and women. 
Similar curves for expected numbers of associated cancers before and after tumour of 
haematopoietic and lymphoid tissues are included in the appendix.
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Figure 18: Expected numbers of associated cancers before tumour of haematopoietic and  
lymphoid tissues: joint model curves (top) and group specific curves (botttom) among women  
(right) and among men (left) [48]
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5.4.3  Detailed analyses of the incidence rates among patients with HL 
5.4.3.1  Age-specific incidence rates of associated solid malignancies in HL patients 
Figure 19: Age-specific incidence rates of associated malignancies: AMN before and after HL 
(top), AMN before HL (bottom), men and women (x: age at diagnosis of HL, y: incidence rate of AMN)
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Because of the high incidence rate of AMN among HL we focused our next analyses on HL. 
Figure 19 describes in detail the incidence rate curves of AMN before and after HL and AMN 
before HL. The x-axis shows the age at diagnosis of HL in 5 year intervall age groups in years. 
The y-axis shows  the incidence rate of AMN in each age group. 
The most  prominently  represented AMN among HL patients are cancer of  breast,  cancer of  
bronchus and lung, cancer of prostate, cancer of colorectum. Cancer of thyroid and cancer of 
oesophagus constitute the cases of AMN in childhood. Table 10 shows the exact numbers of the 
most represented AMN and AMN during childhood according to the age at diagnosis of HL, type 
of AMN and gender. 
Table 10: Numbers of the most prominently represented solid AMN (black) in adults and solid  
AMN in childhood (grey) solid AMN according to the age of diagnosis of HL, type of AMN and 
gender. 
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5.4.3.2  Age-and  gender-specific  incidence  rates  of  associated  solid  malignancies 
among all tumours of haematopoietic and lymphoid tissues and HL 
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Figure 20: Age-and gender-specific incidence rates of solid AMN: before and after all tumours of  
haematopoietic and lymphoid tissues or HL (left); before all tumours of haematopoietic and  
lymphoid tissues or HL (right) (x: age at diagnosis of tumour of haematopoietic and lymphoid tissues, y: incidence rate 
of solid AMN)
Figure 20 shows the age-and gender-specific incidence rates of solid AMN. We compared the 
incidence rates of solid AMN in all patients with tumours of haematopoietic and lymphoid tissues 
with solid AMN in HL patients. Figure 20 shows the incidence rates of solid AMN among men and 
women before and after all tumours of haematopoietic and lymphoid tissues or HL as well as 
before all  tumours of haematopoietic and lymphoid tissues or HL. The x-axis shows the age at 
diagnosis of HL in 5 year intervall age groups in years. The y-axis shows the incidence rates in 
each age group among men and women.
Figure 20 shows that up to 25% of women with HL diagnosed between 20 and 30 years old 
developed  a  previous  or  subsequent  solid  cancer  in  the  study  period  from 1980  and  2008 
(versus 14% in all patients with tumour of haematopoietic and lymphoid tissues in the 25-29 year 
old group). Furthermore almost 30% of women with HL diagnosed between 65 and 74 years old 
had a previous solid AMN in the study period from 1980 and 2008 (versus 13% in all patients 
with tumour of haematopoietic and lymphoid tissues in the 65-69 year old group).
The  RR of  previous solid  malignant  neoplasm in  HL patients  compared to  all  patients  with 
tumours of haematopoietic and lymphoid tissues (except  HL) diagnosed between 65 and 69 
years old is 2,29 among women and 1,31 among men.
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5.4.3.3  Age-and gender-specific incidence rates of cancer of breast, prostate, bronchus 
and lung as well as colon, among all tumours of haematopoietic and lymphoid tissues and 
HL 
Figure 21 a: Age-and gender-specific incidence rates of cancer of breast and prostate: before  
and after all tumours of haematopoietic and lymphoid tissues or HL (left) and before all tumours  
of haematopoietic and lymphoid tissues or HL (right) (x: age at diagnosis of tumour of haematopoietic and 
lymphoid tissues y: incidence rate of a specific AMN)
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Figure 22 b: Age-and gender-specific incidence rates of cancer of bronchus and lung as well as  
colorectum: before and after all tumours of haematopoietic and lymphoid tissues or HL (left) and  
before all tumours of haematopoietic and lymphoid tissues or HL (right) (x: age at diagnosis of tumour of  
haematopoietic and lymphoid tissues , y: incidence rate of a specific AMN)
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Figure 21 shows the age-and gender-specific incidence rates of  cancer of  breast,  cancer  of 
prostate, cancer of bronchus and lung and cancer of colonrectum (colon, rectum and anus). We 
compared  incidence  rates  of  the  specific  solid  AMN  among  all  patients  with  tumours  of 
haematopoietic and lymphoid tissues with incidence rates of the specific solid AMN among HL 
patients.
Figure 21a  shows that most of  AMN before HL are breast cancers.  17% of women with HL 
diagnosed between 65 and 69 years old had a previous cancer of breast in the study period from 
1980 and 2008 (versus 4% in all women with tumours of haematopoietic and lymphoid tissues 
diagnosed between 65 and 69 years old). 
The RR of previous breast cancer in HL compared to all other tumours of haematopoietic and 
lymphoid tissues (except HL) diagnosed between 65 and 69 years old is 3,80.
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5.5  Age-and  time  period  specific  incidence  rates  of  AMN  among  patients  with 
Hodgkin lymphomas 
Figure 23: Age- and time period specific incidence rate curves of solid AMN before and after HL  
(top), before and 1 year after HL (middle) and before HL(bottom), men and women 
(x: age at diagnosis of HL, y: incidence rate of solid AMN)
Figure 23 shows the  incidence rate  curves of  solid  AMN according  to  the age and date  of  
diagnosis of HL. We divided the period from 1980 to 2008 into 3 periods for comparison.
In the time period between 1998 and 2008 AMN are mostly diagnosed before HL. The patients 
diagnosed  between  1998  and  2008  had  less  time  (at  the  time  of  the  study)  to  develop 
subsequent AMN compared to patients diagnosed in 1989-1997 and 1900-1988.
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6  Discussion 
6.1  Numbers of patients, tumours of haematopoietic and lymphoid tissues and AMN 
We analysed  a  population  of  12'798  patients  with  tumours  of  haematopoietic  and lymphoid 
tissues collected in the population based cancer registry of the Canton of Zurich over a period of 
28  years  and  found 2'885  associated  cancers.  After  excluding  patients  with  more  than  one 
cancer of haematopoietic and lymphoid tissues, we detected 2'374 previous and subsequent 
AMN in 10'923 patients. 
We  found  a  significant  number  of  associated  malignant  neoplasms after tumours  of 
haematopoietic  and lymphoid tissues.  Our study is  seminal  in  that  we also investigated the 
inverse case, whether special types of hematopoietic and lymphoid malignancies are preceded 
by an increased number of previous cancers. 
Other studies have previously analysed cancers associated with hematopoietic and lymphoid 
malignancies  [1]-[22][42][43][49]. Some of these reports are summarized in the  Table 2 in the 
introduction.  Some studies include databases of population based cancer registries [1][3][5][6]
[10][11][13]-[15][17]-[19][43][49] or databases of specific institutions like Late Effect Study Group 
member institutions in the study group of Bhatia et al. [1]. Some studies cover a patient database 
of one or several given hospitals  [4][7][8][12][16][20]-[22][42].  The advantages of a population 
based study is to have exact and extensive health-related parameters. Population based studies 
rarely contain biases as they are representative of a given population [50].
Therefore, we consider it a strength of our study that the data was extracted from a population 
based cancer registry. Our results are representative for a population of 1.3 million people in 
Western Europe [44][45].
Some studies have analysed patients with HL [1]-[9]. The highest population  number was 32'591 
patients suffering from HL in the study of Dores et al [3]. In 2002 they discoverd 2'153 secondary 
malignancies over a 25 year period in 16 population-based cancer registries in North America 
and Europe [3]. The smallest analysis was conducted by the study group of Foss Abrahamsen et 
al. In 2002 and they discovered 197 secondary malignancies among 1'024 HL patients [4]. From 
1968 to 1985 they included patients at the beginning of their treatment of HL at the Norwegian 
Radium Hospital  and followed them for second malignancies from 1969 through 1998 in the 
Norwegian  Cancer  Registry  [4].  Some other  studies  covered patients  with  other  tumours  of 
haematopoietic and lymphoid tissues other than HL [10]-[22][42][43][49]. For example, Hisada et 
al. analysed 358 second cancers in 3'104 hairy cell leukaemia survivors, in 16 population-based 
registries in the Surveillance, Epidemiology and End Results (SEER) Programme between 1973 
and 2002 [13]. 
However, few studies mentioned previous and concomitant neoplasms in patients with HL [23]. 
The higher incidence of malignancies in our study in comparison to the above mentioned studies 
is  due to  differences in  the  studied  population.  We analysed associated  malignancies  in  all 
patients with tumours of haematopoietic and lymphoid tissues. That included a majority of older 
patients  in  whom  the  rate  of  malignancy  is  already  high  independently  of  tumours  of  
haematopoietic and lymphoid tissues. The studies which analysed patients with HL [1]-[9] limited 
themselves to patients with HL which is a disease of younger people who have an inherently 
lower baseline cancer rate at young age. We also analysed both previous and subsequent AMN. 
Our numbers therefore tend to be higher than those of studies that focused or were limited on  
subsequent AMN [1]-[22][42][43][49].
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6.2  Average age and sex ratio of patients with AMN 
Our data shows an increased incidence rate of AMN in the older population with haematopoietic 
and lymphoid cancer.  As already mentioned,  this  is  concordant  with  the higher  incidence of 
cancers in elderly persons [51]. 
For some subtypes of tumours of haematopoietic and lymphoid tissues, the incidence rate of  
AMN changed after the age of 80 years. This change can partly be explained by less stringent  
medical procedures to establish a diagnosis in the population aged above 80 years.
We found more men than women with AMN. This is in line with the higher incidence of solid and 
non solid cancer in men [51].
6.3  Numbers of AMN per thousand tumours of haematopoietic and lymphoid tissues 
in patients with AMN 
We found that indolent B cell lymphomas and HL (237cases/1'000 for both) showed the highest  
number of AMN, both for previous and subsequent cancers. HL are diagnosed at an early age 
and have an excellent survival. Indolent B cell lymphomas, though diagnosed later in life also 
show an excellent survival.  Therefore more patients are at risk for the development of  AMN 
compared to other tumours of haematopoietic and lymphoid tissues with a shorter survival rate 
[24].
For other tumours of haematopoietic and lymphoid tissues the incidence of AMN per thousand 
tumours of haematopoietic and lymphoid tissues is low. This is the case with aggressive B cell 
lymphomas (178/1'000),  MM (169/1'000) and ALL (81/1'000),  which all  show higher mortality  
rates and shorter survival rates than patients with HL and indolent B cell lymphomas [24].
Some diagnoses of  tumours  of  haematopoietic  and lymphoid  tissues show excessively  high 
numbers of AMN. These include cancers with lower incidence and therefore fewer registered 
patients.  These  are  namely  extramedullary  plasmocytoma  (324/1'000),  AILT  (271/1'000), 
lymphohistiocytic sarcoma (381/1'000) and LDHL (303/1'000). Some of these associations may 
be due to duplicate coding, such as extramedullary plasmocytoma and MM. Others may be 
representing artefacts of low numbers or they may represent a true feature of the specific tumour 
of haematopoietic and lymphoid tissues.
6.4  Incidence rates of associated malignant neoplasms 
We found a significant number of AMN before and after tumours of haematopoietic and lymphoid 
tissues, especially HL. Our study is concordant with previous studies also showing an increased 
risk  of  associated  cancer  after  tumours  of  haematopoietic  and  lymphoid  tissues,  especially 
childhood HL [1]-[9].
Our analyses show that the most frequent solid cancer preceding HL is breast cancer.  The RR of 
previous breast cancer in HL compared to all patients with other tumours of haematopoietic and  
lymphoid tissues (except HL) diagnosed between 65 and 69 years old is 3,80. Cancers of the 
lung,  colorectum or  prostate  are  also  more  frequently  preceding  HL in  comparison to  other 
tumours  of  haematopoietic  and  lymphoid  tissues.  These  cancers  however  precede  less 
frequently HL than breast cancers do  (13 cases of breast cancers versus 5 cases of prostate 
cancers, 5 cases of colorectal cancers and 4 cases of lung cancers). The numbers are too small 
for meaningful statistical comparison. These associated solid cancers represent the commonest 
cancers in the general population in Switzerland [44]. 
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The finding that HL is more frequently preceded by breast cancer is striking and calling for an 
explanation. We therefore reviewed the literature for previous reports of an increased incidence 
of HL among breast cancer survivors.
6.5  Incidence rates of associated malignant neoplasms in HL patients 
6.5.1  HL among breast cancer survivors 
n the literature some studies analyzed the risk of developing secondary malignancies after breast  
cancer [52]-[55]. A Swiss study included 9'729 breast cancer patients registered by the cancer 
registries of Vaud and Neuchâtel (covering about 786'000 inhabitants),  with a follow up from 
1974 to 1998 [53]. They described an increased standardized incidence ratio (SIR) of 1.38 for  
NHL (95% CI 0.84–2.13), 0.68 for MM (95% CI 0.22–1.58) and 1.20 for leukaemias (95% CI  
0.66–2.02) [53]. No increased SIR was described for HL in the study. A second study identified a 
cohort of 525'527 women with primary breast cancer from 13 population-based cancer registries 
in  Europe,  Canada,  Australia  and  Singapore.  The  study  group  followed  these  women  for 
secondary cancers within the period 1943-2000 [54]. The highest SIR of secondary non breast  
cancers  were  cancers  of  the  stomach,  the  colorectum and  the  lung,  soft  tissue  sarcomas, 
melanomas, non-melanoma skin cancers, endometrium, ovary, kidney, thyroid gland cancers and 
leukaemia. The SIR of developing a secondary cancer after breast cancer was less significant for 
NHL and not significant for HL [54]. A third study analyzed a total of 145'677 Swedish women 
with breast cancer diagnosed between 1961 and 1995. No significant increase of the incidences 
of NHL, MM, lymphoid leukaemia after breast cancer was shown. But an increased incidence of 
myeloid leukaemia (breast cancer diagnosed at age < 50, SIR of 2.31 with CI 1.52-3.51) could be 
shown [55]. In conclusion cases of non solid malignancies following breast cancer have been 
described in the literature but they are not as predominantly represented as solid cancers.
We also reviewed common etiological factors which could induce HL and cancers of the breast, 
lung, prostate or colorectum in order to explain our results. 
6.5.2  Common etiological factors of HL and cancers of the breast, lung, prostate 
or colorectum 
6.5.2.1  Genetic factors and tumours of haematopoietic and lymphoid tissues 
A multicentric case control study from Sweden and Denmark compared the risk of  secondary 
cancers associated with a family history of any cancer in patients with HL. They observed an 
isolated  increased  relative  risk  (1.81,  95%  CI  1.04–3.16)  of  breast  cancer  as  a  secondary 
malignancy  among  HL patient  with  positive  (versus  negative)  family  history  of  cancer.  The 
increased risks of breast cancer among HL patients with  positive family history of any cancer 
suggests in part  a common  genetic  factor  [56]. Though, the idea of common genetic factors 
between HL and breast cancer is controversial in the literature. On one hand, genetic mutations  
of TP53,  BRCA1,  BRCA2  and  ataxia  telangiectasia  genes  were  not  frequently  observed  in 
cohorts of HL patients developing secondary malignant neoplasms [57][58]. On the other hand, a 
meta  analysis  concluded  that  an  intact  BRCA1  and  2  pathway  protects  from haematologic 
cancer in addition to breast and ovarian cancers  [59]. A genetic defect in the BRCA pathway 
increases  the  risk  of  developing  haematologic  cancers  up  to  nearly  2000  fold  for  certain 
leukemias and lymphomas (mostly MCL, AML, ALL, CLL and LPL). An increased risk of HL was 
not observed [59]. Finally we found no clear common genetic etiological factors in the literature, 
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which could explain the increased incidence rate of breast cancer preceding HL. 
No common genetic risk factors are found in the literature between HL and cancer of  lung. 
Secondary  p53  mutations  following  radiotherapy  in  HL patients  may  cause  some  radiation-
induced cancers like lung cancers [60].
6.5.2.2  Lifestyle and occupational exposure and tumours of haematopoietic and 
lymphoid tissues 
The role of tobacco in the carcinogenesis is well established in lung cancer patients. Its role  
seems to be stronger in HL (however not always statistically significant ) compared to NHL [61]. 
Increased risk after tobacco exposure has also been described for specific NHL, namely FL 
among women [61][61]. On the one hand some studies have reported a significantly higher risk 
of secondary lung cancers in HL patients among smokers compared to non smokers and on the 
other hand others have not found an higher risk [63].
In our study we analysed incidence rates of lymphoma subtypes and tobacco-induced cancers 
(especially cancers of the head, neck and the bladder). We did not find an increased incidence of  
tobacco-induced cancers other than lung cancer, especially among HL and FL patients. 
A causal association between exposure to benzene and an increased risk of leukaemia is well-
established, as well as a presumptive risk of lung cancer [64]. In addition to NHL and prostate 
cancer several others cancers may be linked to a variety of pesticides (namely cancers of the 
breast, the colorectum, the lung) [65]. But no chemical substances (e.g. solvents, pesticides) are 
known according to literature to increase the incidence of HL and cancers of the prostate, lung, 
breast and colorectum.
We found no common environmental etiological factors in the literature which could explain the 
increased incidence of breast cancer preceding HL.
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6.5.2.3  Immunosuppression and tumours of haematopoietic and lymphoid tissues 
Among HIV patients increased incidences of HL (RR 11.5,  95% CI 10.6-12.5) and lung cancer 
(RR 4.5, 95% CI 4.2-4.8) have been observed in the USA suggesting a potential association of 
these two cancers with immunosuppression [66]. However, lung cancer may have occurred in 
excess in persons with HIV/AIDS because of heavy smoking [66]. 
Ulcerative colitis patients are at an increased risk of colorectal, hepatobiliary, non melanoma skin 
cancers  and  acute  myeloid  leukaemia.  An  increased  risk  of  HL was  not  observed among 
ulcerative colitis patients [67]. 
The majority of malignancies after blood or marrow stem-cell transplantation are NHL, HL or solid 
tumours,  namely melanoma,  brain,  and oral  cavity  tumours  [68][69].  The literature does not 
indicate a significantly increased incidence of cancer of the breast, the lung, the colorectum and 
the prostate after blood or marrow stem-cell transplantation. 
The most frequent cancers after organ transplantation are malignant lymphomas and cutaneous 
neoplasms [70]. The observed incidence rates of malignancies in patients after transplantation 
range from 4.1% to 16% in different series. Although a decreased incidence of breast cancers  
has  been  reported  after  organ  transplantation  in  the  literature,  there  is  contradictory  data 
concerning the incidence of breast cancer in those patients compared with the overall population 
[70]. 
Tumour-mediated  immunosuppression  following  breast,  lung,  colorectal  and  prostate  cancer, 
may represent an etiological factor and induce hypothetically an adequate environment for HL, 
but  review  of  the  literature  shows that  evidence  in  supporting  this  hypothesis  is  limited.  In  
comparison with renal cell carcinoma or melanomas considered as highly immunogenic, breast 
cancer  is  a  weak  immunogenic  tumor  [71].  Colorectal  [72] and prostate  cancers  [73] are 
potentially immunogenic. The clinical research in this domain is however still under development 
[74]. 
We found no common immunological etiological factors in the literature which could explain the 
increased incidence of breast cancer preceding HL.
6.5.2.4  Infection and tumours of haematopoietic and lymphoid tissues 
Parallel  to  its  established  causal  association  with  both  infectious  mononucleosis  and  young 
adulthood  HL,  a  descriptive  and  a  population  based  case  control  study  [75] proposed  a 
hypothesis in 2001 that “delayed” primary EBV infection (i.e., primary infection occurring during 
adolescence or adulthood) is associated with an elevated risk of developing breast cancer. Using 
an international/United States cancer registry data, they observed similarities between incidence 
rates  among  women  of  young  adulthood  HL (mostly  nodular  sclerosis  subtype),  “delayed” 
primary EBV infection and breast cancer. The analytical study analysed the age adjusted ratio of  
breast cancers in women who reported a history of early or late infectious mononucleosis (odds 
ratio of breast cancer in women with early infection (0-9 years of age) of 0.55 versus 2.67 in 
women with late infection (>25 years of age))  [75]. A “delayed” EBV infection thus may be an 
etiological factor for HL and breast cancer. Another study published in 2008 analysed the breast  
cancer risk in association with microbial cancer (cervical, liver and stomach cancers associated 
with HPV, hepatitis viruses and helicobacter pylori) in 74 women populations around the world. 
Their deducted hypothesis was that breast cancer etiology may have an appreciable link with  
microbial exposure (and/or immunological response to them). The lack of microbial exposure, 
especially in early life, may elevate breast cancer risk [76]. Our data however does not allow for 
an interpretation of these studies. 
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6.5.2.5  Therapy and tumours of haematopoietic and lymphoid tissues 
Therapy of breast cancer like breast irradiation, adjuvant chemotherapy, and tamoxifen treatment  
is  associated with  an increased risk of  secondary cancers that  may manifest  decades later. 
Chemotherapy with alkylating agents (e.g. cyclophosphamide), topoisomerase II inhibitors and 
antracycline antibiotics (doxorubicin and epirubicin) can be associated with leukaemias [77]. HL 
could be hypothetically the complication of the treatment of breast and lung cancer (alkylating 
agents, topoisomerase inhibitors and radiotherapy). In the literature no clear evidence showed a 
direct  association between breast  cancer therapy and occurrence of following HL. Moreover, 
other tumours of haematopoietic and lymphoid tissues like AML that are known to be increased 
after such therapies, were not found to be increased in our study.
6.6  Clinical implications 
Because  of  the  remarkable  gains  in  survival  attributable  to  successful  treatment  of  HL, 
secondary malignancies are actually the leading cause of  death among HL survivors.  In the 
literature, the necessity of long term follow-up screening programs among young HL survivors 
are  well  documented [78][79].  Our  findings  suggest  that  when  HL is  diagnosed  in  an  older 
person,  a  search  for  concomitant  immunomodulation  such  as  caused  by  an  auto-immune 
disease or a secondary cancer must be undertaken. Moreover enlarged lymph nodes among 
breast cancer survivors may also represent the manifestation of HL.
7  Conclusion 
We show herein for the first time that HL are not only associated with later malignancies but that  
they are also associated with  previous malignant  neoplasms, mostly  breast  cancer and less 
significantly cancers of the lung, the colorectum and the prostate. The reason for this association 
of previous malignant tumours with later HL may include common genetic risk factors, direct  
genotoxic therapy effects and immunomodulation due to therapy or due to the cancer itself. In  
the literature, the only clear common etiological factor is a delayed EBV infection which could 
induce both HL and breast cancer. Further studies could therefore include investigation of EBV 
states in both HL and breast cancer patients. Moreover analyses with more patients must be  
undertaken to confirm the data. Our study may prompt for a systematic search for solid cancers 
in patients diagnosed with HL at an advanced age.
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9  Appendix 
9.1  Scatter diagrams 
The  next  figures  show,  in  alphabetic  order,  scatter  diagrams  of  subtypes  of 
lymphohaematopoietic cancers and their associated malignancies. The x-axis shows the time 
interval between the tumour of haematopoietic and lymphoid tissues and the associated cancer 
in  years.  The  y-axis  shows  age  at  diagnosis  of  lymphohaematopoietic  cancer  in  years. 
Furthermore calendar years of diagnosis of the lymphohaematopoietic cancer are indicated with 
different  symbols  (in  the  legend).  There  are  shown  two  figures  per  subtype  of  tumour  of  
haematopoietic and lymphoid tissues. The first figure shows all associated cancers (solid and 
non solid cancers) and the subtype of lymphohaematopoietic cancer. The second figure shows 
solid associated cancer and the subtype of lymphohaematopoietic cancer.
9.1.1  Associated cancers and AILT 
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9.1.2  Associated cancers and AML 
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9.1.3  Associated cancers and anaplastic large cell lymphoma 
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9.1.4  Associated cancers and Burkitt lymphoma, indeterminate NHL and non 
Burkitt NHL 
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9.1.5  Associated cancers and CML and MPD NOS 
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9.1.6  Associated cancers and diffuse centroblastic centrocytic lymphoma 
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9.1.7  Associated cancers and DLBL 
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9.1.8  Associated cancers and extramedullary plasmocytoma 
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9.1.9  Associated cancers and FL 
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9.1.10  Associated cancers and HCL 
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9.1.11  Associated cancers and HL NOS 
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9.1.12  Associated cancers and histiocytic lymphoma 
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9.1.13  Associated cancers and ALL 
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9.1.14  Associated cancers and LDHL 
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9.1.15  Associated cancers and LPL 
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9.1.16  Associated cancers and MCL 
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9.1.17  Associated cancers and marginal zone lymphoma 
77
9.1.18  Associated cancers and MCHL 
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9.1.19  Associated cancers and MDS 
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9.1.20  Associated cancers and MM 
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9.1.21  Associated cancers and Mycosis fungoides including Sezary syndrome 
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9.1.22  Associated cancers and NLPHL 
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9.1.23  Associated cancers and NSHL 
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9.1.24  Associated cancers and prolymphocytic lymphoma 
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9.1.25  Associated cancers and SLL-CLL 
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9.1.26  Associated cancers and T cell lymphoma 
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9.2  Incidence rates of associated malignant neoplasms 
9.2.1  Cancer of breast 
The following figures show the incidence rate curves of breast cancer associated with tumours of  
haematopoietic and lymphoid tissues (HL, MM, HPSCD, FL, CLL, MCL, LPL and DLBL) among 
women.  The  first  part  shows  the  incidence  rate  curves  of  breast  cancer  before  and  after  
lymphohaematopoietic cancers (before+after). The second part shows incidence rate curves of 
breast cancer before and one year after lymphohaematopoietic cancers (before+1 year). The last  
part  shows the incidence rate curves of breast cancer before lymphohaematopoietic cancers 
(before)  The  x-axis  shows  the  age  of  diagnosis  of  lymphohaematopoietic  cancer  in  5  year 
intervall age groups. The y-axis shows the incidence rate of cancer of breast in each age group. 
The table after the figures show the individual data points of the figures.
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(HPSCD: ALL, AML, CML and MDS)
88
Individual data points for breast cancers
name age range number of lymphoma 
number of cancer of 
breast (before and after)
number of cancer of 
breast (before+1 year)
number of 
cancer of breast 
(before)
HL
0-4 0 0 0 0
5-9 2 0 0 0
10-14 15 0 0 0
15-19 37 6 0 0
20-24 62 5 0 0
25-29 51 5 0 0
30-34 56 4 0 0
35-39 32 2 0 0
40-44 31 3 0 0
45-49 14 1 0 0
50-54 18 1 0 0
55-59 13 1 1 1
60-64 19 4 2 2
65-69 27 5 4 4
70-74 16 3 3 3
75-79 23 4 3 3
80-84 13 0 0 0
85-89 8 1 1 1
FL
0-4 0 0 0 0
5-9 0 0 0 0
10-14 0 0 0 0
15-19 0 0 0 0
20-24 1 0 0 0
25-29 0 0 0 0
30-34 3 0 0 0
35-39 12 0 0 0
40-44 17 1 0 0
45-49 28 1 1 1
50-54 44 1 0 0
55-59 42 3 3 3
60-64 36 2 2 2
65-69 31 3 2 2
70-74 36 2 2 2
75-79 29 4 4 4
80-84 23 2 2 2
85-89 16 1 1 1
LPL
0-4 0 0 0 0
5-9 0 0 0 0
10-14 0 0 0 0
89
LPL
15-19 0 0 0 0
20-24 0 0 0 0
25-29 0 0 0 0
30-34 2 0 0 0
35-39 1 0 0 0
40-44 3 1 1 0
45-49 5 0 0 0
50-54 13 0 0 0
55-59 29 1 1 1
60-64 19 3 2 2
65-69 32 4 3 3
70-74 35 1 1 1
75-79 34 1 0 0
80-84 31 0 0 0
85-89 16 2 2 2
MM
0-4 0 0 0 0
5-9 0 0 0 0
10-14 0 0 0 0
15-19 1 0 0 0
20-24 0 0 0 0
25-29 0 0 0 0
30-34 0 0 0 0
35-39 6 0 0 0
40-44 18 0 0 0
45-49 20 0 0 0
50-54 48 2 1 1
55-59 60 1 1 1
60-64 82 5 5 5
65-69 128 5 3 3
70-74 163 11 8 8
75-79 159 10 10 9
80-84 150 8 7 7
85-89 72 6 5 5
CLL
0-4 0 0 0 0
5-9 0 0 0 0
10-14 0 0 0 0
15-19 1 0 0 0
20-24 0 0 0 0
25-29 3 0 0 0
30-34 2 0 0 0
35-39 11 1 0 0
40-44 12 1 0 0
45-49 21 2 2 1
90
CLL
50-54 37 2 2 2
55-59 74 6 5 4
60-64 87 14 9 9
65-69 108 13 9 9
70-74 146 14 13 12
75-79 168 14 12 12
80-84 137 10 8 8
85-89 92 9 7 7
DLBL
0-4 1 0 0 0
5-9 3 0 0 0
10-14 1 0 0 0
15-19 12 0 0 0
20-24 12 0 0 0
25-29 19 1 1 1
30-34 25 0 0 0
35-39 23 0 0 0
40-44 29 0 0 0
45-49 32 0 0 0
50-54 42 0 0 0
55-59 68 2 2 2
60-64 87 5 2 2
65-69 81 6 3 3
70-74 123 6 6 6
75-79 150 6 6 6
80-84 131 10 10 10
85-89 84 6 6 6
HPSCD: ALL, AML, 
CML, MDS
0-4 49 0 0 0
5-9 32 0 0 0
10-14 14 0 0 0
15-19 14 0 0 0
20-24 20 0 0 0
25-29 25 0 0 0
30-34 32 0 0 0
35-39 36 2 1 1
40-44 52 2 1 1
45-49 51 0 0 0
50-54 69 2 2 2
55-59 83 6 4 4
60-64 93 6 5 5
65-69 150 3 2 2
70-74 180 5 5 5
75-79 212 9 9 8
80-84 183 8 7 7
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HPSCD 85-89 114 3 3 3
MCL
0-4 0 0 0 0
5-9 0 0 0 0
10-14 0 0 0 0
15-19 0 0 0 0
20-24 0 0 0 0
25-29 1 0 0 0
30-34 0 0 0 0
35-39 1 0 0 0
40-44 2 0 0 0
45-49 1 0 0 0
50-54 5 0 0 0
55-59 6 0 0 0
60-64 12 1 0 0
65-69 13 1 0 0
70-74 9 0 0 0
75-79 15 1 1 1
80-84 19 1 1 1
85-89 7 0 0 0
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9.2.2  Cancer of colon 
The following figures show the incidence rate curves of colon cancer associated with tumours of 
haematopoietic and lymphoid tissues among women and men. The first part shows the incidence 
rate curves of cancer of colon before and after lymphohaematopoietic cancers (before+after). 
The second part shows incidence rate curves of cancer of colon before and one year after 
lymphohaematopoietic cancers (before+1 year). The last part shows the incidence rate curves of 
cancer of colon before lymphohaematopoietic cancers (before). The x-axis shows the age of 
diagnosis of lymphohaematopoietic cancer in 5 year intervall age groups in years. The y-axis 
shows the incidence rates of cancer of colon in each age group. 
The table after the figures show the individual data points of the figures.
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(HPSCD: ALL, AML, CML and MDS)
94
(HPSCD: ALL, AML, CML and MDS)
95
(HPSCD: ALL, AML, CML and MDS)
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Individual data points for colon cancer (N: number)
name
age 
range
N 
lympho
haemat
opoietic 
cancer
N colon cancer   
N 
lympho
haemat
opoietic 
cancer
N colon cancer
N 
lympho
haemat
opoietic 
cancer 
N colon cancer 
before 
and after
before+
1 year before
before 
and after
before+
1 year before
before 
and after
before+1 
year before
Total M F
HL
0-4 1 0 0 0 1 0 0 0 0 0 0 0
5-9 9 0 0 0 7 0 0 0 2 0 0 0
10-14 30 0 0 0 15 0 0 0 15 0 0 0
15-19 67 0 0 0 30 0 0 0 37 0 0 0
20-24 125 0 0 0 63 0 0 0 62 0 0 0
25-29 107 0 0 0 56 0 0 0 51 0 0 0
30-34 120 3 0 0 64 2 0 0 56 1 0 0
35-39 90 1 0 0 58 1 0 0 32 0 0 0
40-44 99 1 0 0 68 1 0 0 31 0 0 0
45-49 47 0 0 0 33 0 0 0 14 0 0 0
50-54 55 0 0 0 37 0 0 0 18 0 0 0
55-59 50 0 0 0 37 0 0 0 13 0 0 0
60-64 42 2 0 0 23 1 0 0 19 1 0 0
65-69 58 2 1 1 31 1 1 1 27 1 0 0
70-74 37 1 1 1 21 1 1 1 16 0 0 0
75-79 39 0 0 0 16 0 0 0 23 0 0 0
80-84 20 1 1 1 7 0 0 0 13 1 1 1
85-89 15 1 1 1 7 1 1 1 8 0 0 0
FL
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 1 0 0 0 1 0 0 0 0 0 0 0
20-24 2 0 0 0 1 0 0 0 1 0 0 0
25-29 3 0 0 0 3 0 0 0 0 0 0 0
30-34 8 0 0 0 5 0 0 0 3 0 0 0
35-39 22 1 1 0 10 0 0 0 12 1 1 0
40-44 31 0 0 0 14 0 0 0 17 0 0 0
45-49 44 0 0 0 16 0 0 0 28 0 0 0
50-54 78 0 0 0 34 0 0 0 44 0 0 0
55-59 77 3 1 1 35 1 0 0 42 2 1 1
60-64 67 1 1 1 31 0 0 0 36 1 1 1
65-69 70 1 0 0 39 1 0 0 31 0 0 0
70-74 57 0 0 0 21 0 0 0 36 0 0 0
75-79 49 1 1 1 20 1 1 1 29 0 0 0
80-84 35 0 0 0 12 0 0 0 23 0 0 0
85-89 18 0 0 0 2 0 0 0 16 0 0 0
LPL
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 1 0 0 0 1 0 0 0 0 0 0 0
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LPL
15-19 0 0 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0 0 0
25-29 2 0 0 0 2 0 0 0 0 0 0 0
30-34 3 0 0 0 1 0 0 0 2 0 0 0
35-39 3 0 0 0 2 0 0 0 1 0 0 0
40-44 11 0 0 0 8 0 0 0 3 0 0 0
45-49 18 2 1 0 13 1 1 0 5 1 0 0
50-54 31 0 0 0 18 0 0 0 13 0 0 0
55-59 51 2 2 2 22 1 1 1 29 1 1 1
60-64 39 1 1 1 20 1 1 1 19 0 0 0
65-69 66 1 1 1 34 0 0 0 32 1 1 1
70-74 75 1 1 1 40 1 1 1 35 0 0 0
75-79 71 1 0 0 37 0 0 0 34 1 0 0
80-84 69 1 0 0 38 0 0 0 31 1 0 0
85-89 36 0 0 0 20 0 0 0 16 0 0 0
MM
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 1 0 0 0 0 0 0 0 1 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0 0 0
25-29 1 0 0 0 1 0 0 0 0 0 0 0
30-34 2 0 0 0 2 0 0 0 0 0 0 0
35-39 17 0 0 0 11 0 0 0 6 0 0 0
40-44 45 0 0 0 27 0 0 0 18 0 0 0
45-49 64 0 0 0 44 0 0 0 20 0 0 0
50-54 91 2 0 0 43 1 0 0 48 1 0 0
55-59 163 4 3 3 103 2 2 2 60 2 1 1
60-64 194 0 0 0 112 0 0 0 82 0 0 0
65-69 278 2 2 1 150 2 2 1 128 0 0 0
70-74 326 3 1 1 163 1 1 1 163 2 0 0
75-79 320 9 5 5 161 3 0 0 159 6 5 5
80-84 266 3 3 3 116 0 0 0 150 3 3 3
85-89 134 5 5 5 62 2 2 2 72 3 3 3
CLL
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 3 0 0 0 2 0 0 0 1 0 0 0
20-24 2 0 0 0 2 0 0 0 0 0 0 0
25-29 6 0 0 0 3 0 0 0 3 0 0 0
30-34 5 0 0 0 3 0 0 0 2 0 0 0
35-39 23 0 0 0 12 0 0 0 11 0 0 0
40-44 31 0 0 0 19 0 0 0 12 0 0 0
45-49 53 0 0 0 32 0 0 0 21 0 0 0
50-54 108 0 0 0 71 0 0 0 37 0 0 0
55-59 168 2 1 0 94 0 0 0 74 2 1 0
60-64 242 3 1 1 155 3 1 1 87 0 0 0
CLL
65-69 271 4 1 1 163 0 0 0 108 4 1 1
70-74 325 11 6 6 179 8 5 5 146 3 1 1
75-79 354 2 2 1 186 0 0 0 168 2 2 1
80-84 264 7 6 6 127 5 4 4 137 2 2 2
85-89 180 6 5 4 88 2 2 2 92 4 3 2
DLBL
0-4 2 0 0 0 1 0 0 0 1 0 0 0
5-9 12 0 0 0 9 0 0 0 3 0 0 0
10-14 4 0 0 0 3 0 0 0 1 0 0 0
15-19 23 0 0 0 11 0 0 0 12 0 0 0
20-24 24 0 0 0 12 0 0 0 12 0 0 0
25-29 48 0 0 0 29 0 0 0 19 0 0 0
30-34 67 1 1 1 42 0 0 0 25 1 1 1
35-39 78 0 0 0 55 0 0 0 23 0 0 0
40-44 78 0 0 0 49 0 0 0 29 0 0 0
45-49 94 0 0 0 62 0 0 0 32 0 0 0
50-54 120 0 0 0 78 0 0 0 42 0 0 0
55-59 161 3 1 1 93 2 1 1 68 1 0 0
60-64 178 0 0 0 91 0 0 0 87 0 0 0
65-69 184 1 1 1 103 0 0 0 81 1 1 1
70-74 256 3 2 2 133 1 0 0 123 2 2 2
75-79 276 6 6 5 126 3 3 2 150 3 3 3
80-84 242 4 4 4 111 3 3 3 131 1 1 1
85-89 132 2 2 2 48 1 1 1 84 1 1 1
HPSCD:
ALL, AML, 
CML, MDS
0-4 134 0 0 0 85 0 0 0 49 0 0 0
5-9 74 0 0 0 42 0 0 0 32 0 0 0
10-14 49 0 0 0 35 0 0 0 14 0 0 0
15-19 35 0 0 0 21 0 0 0 14 0 0 0
20-24 59 0 0 0 39 0 0 0 20 0 0 0
25-29 71 0 0 0 46 0 0 0 25 0 0 0
30-34 62 0 0 0 30 0 0 0 32 0 0 0
35-39 89 0 0 0 53 0 0 0 36 0 0 0
40-44 109 1 1 1 57 0 0 0 52 1 1 1
45-49 114 2 0 0 63 2 0 0 51 0 0 0
50-54 144 0 0 0 75 0 0 0 69 0 0 0
55-59 184 1 1 1 101 1 1 1 83 0 0 0
60-64 239 2 1 1 146 1 0 0 93 1 1 1
65-69 314 1 1 0 164 1 1 0 150 0 0 0
70-74 430 12 10 8 250 9 7 5 180 3 3 3
75-79 463 12 10 8 251 10 8 6 212 2 2 2
80-84 354 13 10 7 171 8 6 5 183 5 4 2
85-89 201 4 4 4 87 2 2 2 114 2 2 2
MCL
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 0 0 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0 0 0
99
MCL
25-29 1 0 0 0 0 0 0 0 1 0 0 0
30-34 3 0 0 0 3 0 0 0 0 0 0 0
35-39 5 0 0 0 4 0 0 0 1 0 0 0
40-44 6 0 0 0 4 0 0 0 2 0 0 0
45-49 6 1 0 0 5 1 0 0 1 0 0 0
50-54 16 0 0 0 11 0 0 0 5 0 0 0
55-59 24 0 0 0 18 0 0 0 6 0 0 0
60-64 35 1 1 1 23 0 0 0 12 1 1 1
65-69 52 0 0 0 39 0 0 0 13 0 0 0
70-74 34 2 1 1 25 2 1 1 9 0 0 0
75-79 39 0 0 0 24 0 0 0 15 0 0 0
80-84 34 0 0 0 15 0 0 0 19 0 0 0
85-89 10 0 0 0 3 0 0 0 7 0 0 0
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9.2.3  Cancer of lung 
The following figures show the incidence rate curves of lung cancer associated with tumours of 
haematopoietic and lymphoid tissues among women and men. The first part shows the incidence 
rate curves of cancer of lung before and after lymphohaematopoietic cancers (before+after). The 
second  part  shows  incidence  rate  curves  of  cancer  of  lung  before  and  one  year  after 
lymphohaematopoietic cancers (before+1 year). The last part shows the incidence rate curves of 
cancer  of  lung before lymphohaematopoietic  cancers (before).  The x-axis  shows the  age of  
diagnosis of lymphohaematopoietic cancer in 5 year intervall age groups in years. The y-axis 
shows the incidence rates of cancer of lung in each age group. 
The table after the figures show the individual data points of the figures.
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(HPSCD: ALL, AML, CML and MDS)
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(HPSCD: ALL, AML, CML and MDS)
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(HPSCD: ALL, AML, CML and MDS)
104
individual data points for lung cancer (N: numbers)
name
age 
range
N 
lympho
haemat
opoietic 
cancer
N lung cancer
N 
lympho
haemat
opoietic 
cancer
N lung cancer
N 
lympho
haemat
opoietic 
cancer
N lung cancer
before 
and after
before+
1 year before
before 
and after
before+
1 year before
before 
and after
before+
1 year before
Total M F
HL
0-4 1 0 0 0 1 0 0 0 0 0 0 0
5-9 9 0 0 0 7 0 0 0 2 0 0 0
10-14 30 0 0 0 15 0 0 0 15 0 0 0
15-19 67 1 0 0 30 0 0 0 37 1 0 0
20-24 125 4 0 0 63 2 0 0 62 2 0 0
25-29 107 6 0 0 56 2 0 0 51 4 0 0
30-34 120 7 0 0 64 6 0 0 56 1 0 0
35-39 90 5 0 0 58 5 0 0 32 0 0 0
40-44 99 4 0 0 68 3 0 0 31 1 0 0
45-49 47 3 0 0 33 3 0 0 14 0 0 0
50-54 55 3 0 0 37 3 0 0 18 0 0 0
55-59 50 4 2 2 37 3 1 1 13 1 1 1
60-64 42 2 2 2 23 2 2 2 19 0 0 0
65-69 58 2 1 0 31 2 1 0 27 0 0 0
70-74 37 1 1 0 21 1 1 0 16 0 0 0
75-79 39 0 0 0 16 0 0 0 23 0 0 0
80-84 20 0 0 0 7 0 0 0 13 0 0 0
85-89 15 0 0 0 7 0 0 0 8 0 0 0
FL
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 1 0 0 0 1 0 0 0 0 0 0 0
20-24 2 0 0 0 1 0 0 0 1 0 0 0
25-29 3 0 0 0 3 0 0 0 0 0 0 0
30-34 8 0 0 0 5 0 0 0 3 0 0 0
35-39 22 0 0 0 10 0 0 0 12 0 0 0
40-44 31 0 0 0 14 0 0 0 17 0 0 0
45-49 44 0 0 0 16 0 0 0 28 0 0 0
50-54 78 1 1 1 34 0 0 0 44 1 1 1
55-59 77 5 0 0 35 4 0 0 42 1 0 0
60-64 67 1 0 0 31 0 0 0 36 1 0 0
65-69 70 1 1 1 39 1 1 1 31 0 0 0
70-74 57 1 0 0 21 1 0 0 36 0 0 0
75-79 49 0 0 0 20 0 0 0 29 0 0 0
80-84 35 0 0 0 12 0 0 0 23 0 0 0
85-89 18 0 0 0 2 0 0 0 16 0 0 0
LPL 0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 1 0 0 0 1 0 0 0 0 0 0 0
105
LPL
15-19 0 0 0 0 0 0 0 0 0 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0 0 0
25-29 2 0 0 0 2 0 0 0 0 0 0 0
30-34 3 0 0 0 1 0 0 0 2 0 0 0
35-39 3 0 0 0 2 0 0 0 1 0 0 0
40-44 11 0 0 0 8 0 0 0 3 0 0 0
45-49 18 0 0 0 13 0 0 0 5 0 0 0
50-54 31 0 0 0 18 0 0 0 13 0 0 0
55-59 51 2 0 0 22 2 0 0 29 0 0 0
60-64 39 3 0 0 20 3 0 0 19 0 0 0
65-69 66 2 1 0 34 2 1 0 32 0 0 0
70-74 75 3 2 2 40 3 2 2 35 0 0 0
75-79 71 1 0 0 37 0 0 0 34 1 0 0
80-84 69 1 1 1 38 1 1 1 31 0 0 0
85-89 36 0 0 0 20 0 0 0 16 0 0 0
MM
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 1 0 0 0 0 0 0 0 1 0 0 0
20-24 0 0 0 0 0 0 0 0 0 0 0 0
25-29 1 0 0 0 1 0 0 0 0 0 0 0
30-34 2 0 0 0 2 0 0 0 0 0 0 0
35-39 17 0 0 0 11 0 0 0 6 0 0 0
40-44 45 0 0 0 27 0 0 0 18 0 0 0
45-49 64 0 0 0 44 0 0 0 20 0 0 0
50-54 91 1 1 1 43 1 1 1 48 0 0 0
55-59 163 2 0 0 103 2 0 0 60 0 0 0
60-64 194 3 1 1 112 3 1 1 82 0 0 0
65-69 278 3 2 2 150 3 2 2 128 0 0 0
70-74 326 4 3 3 163 3 3 3 163 1 0 0
75-79 320 4 2 2 161 3 2 2 159 1 0 0
80-84 266 2 2 0 116 0 0 0 150 2 2 0
85-89 134 4 3 3 62 1 1 1 72 3 2 2
CLL
0-4 0 0 0 0 0 0 0 0 0 0 0 0
5-9 0 0 0 0 0 0 0 0 0 0 0 0
10-14 0 0 0 0 0 0 0 0 0 0 0 0
15-19 3 0 0 0 2 0 0 0 1 0 0 0
20-24 2 0 0 0 2 0 0 0 0 0 0 0
25-29 6 0 0 0 3 0 0 0 3 0 0 0
30-34 5 0 0 0 3 0 0 0 2 0 0 0
35-39 23 1 0 0 12 1 0 0 11 0 0 0
40-44 31 2 0 0 19 2 0 0 12 0 0 0
45-49 53 0 0 0 32 0 0 0 21 0 0 0
50-54 108 0 0 0 71 0 0 0 37 0 0 0
55-59 168 6 4 3 94 4 3 2 74 2 1 1
60-64 242 7 1 0 155 6 1 0 87 1 0 0
106
CLL
65-69 271 11 5 4 163 8 3 3 108 3 2 1
70-74 325 10 5 5 179 8 5 5 146 2 0 0
75-79 354 10 7 7 186 8 5 5 168 2 2 2
80-84 264 6 3 3 127 6 3 3 137 0 0 0
85-89 180 0 0 0 88 0 0 0 92 0 0 0
DLBL
0-4 2 0 0 0 1 0 0 0 1 0 0 0
5-9 12 0 0 0 9 0 0 0 3 0 0 0
10-14 4 0 0 0 3 0 0 0 1 0 0 0
15-19 23 0 0 0 11 0 0 0 12 0 0 0
20-24 24 0 0 0 12 0 0 0 12 0 0 0
25-29 48 0 0 0 29 0 0 0 19 0 0 0
30-34 67 1 0 0 42 1 0 0 25 0 0 0
35-39 78 1 1 1 55 1 1 1 23 0 0 0
40-44 78 0 0 0 49 0 0 0 29 0 0 0
45-49 94 0 0 0 62 0 0 0 32 0 0 0
50-54 120 3 0 0 78 3 0 0 42 0 0 0
55-59 161 0 0 0 93 0 0 0 68 0 0 0
60-64 178 5 1 1 91 4 1 1 87 1 0 0
65-69 184 5 4 4 103 5 4 4 81 0 0 0
70-74 256 1 0 0 133 1 0 0 123 0 0 0
75-79 276 5 5 5 126 3 3 3 150 2 2 2
80-84 242 2 1 1 111 2 1 1 131 0 0 0
85-89 132 3 3 2 48 3 3 2 84 0 0 0
HPSCD: 
ALL, AML, 
CML, MDS
0-4 134 0 0 0 85 0 0 0 49 0 0 0
5-9 74 0 0 0 42 0 0 0 32 0 0 0
10-14 49 0 0 0 35 0 0 0 14 0 0 0
15-19 35 0 0 0 21 0 0 0 14 0 0 0
20-24 59 0 0 0 39 0 0 0 20 0 0 0
25-29 71 0 0 0 46 0 0 0 25 0 0 0
30-34 62 0 0 0 30 0 0 0 32 0 0 0
35-39 89 0 0 0 53 0 0 0 36 0 0 0
40-44 109 0 0 0 57 0 0 0 52 0 0 0
45-49 114 1 1 1 63 0 0 0 51 1 1 1
50-54 144 1 1 1 75 0 0 0 69 1 1 1
55-59 184 1 1 0 101 0 0 0 83 1 1 0
60-64 239 4 3 3 146 3 3 3 93 1 0 0
65-69 314 5 2 2 164 4 2 2 150 1 0 0
70-74 430 13 9 8 250 10 8 8 180 3 1 0
75-79 463 2 2 1 251 1 1 1 212 1 1 0
80-84 354 2 2 2 171 2 2 2 183 0 0 0
85-89 201 3 3 3 87 3 3 3 114 0 0 0
MCL
0-4 0 0 0 0 0 0 0 0 0 0 0 o
5-9 0 0 0 0 0 0 0 0 0 0 0 o
10-14 0 0 0 0 0 0 0 0 0 0
MCL 15-19 0 0 0 0 0 0 0 0 0 0 0 o
20-24 0 0 0 0 0 0 0 0 0 0 0 o
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25-29 1 0 0 0 0 0 0 0 1 0 0 o
30-34 3 0 0 0 3 0 0 0 0 0 0 o
35-39 5 0 0 0 4 0 0 0 1 0 0 o
40-44 6 0 0 0 4 0 0 0 2 0 0 o
45-49 6 0 0 0 5 0 0 0 1 0 0 o
50-54 16 0 0 0 11 0 0 0 5 0 0 o
55-59 24 0 0 0 18 0 0 0 6 0 0 o
60-64 35 1 0 0 23 0 0 0 12 1 0 o
65-69 52 2 1 1 39 2 1 1 13 0 0 o
70-74 34 1 0 0 25 0 0 0 9 1 0 o
75-79 39 1 0 0 24 1 0 0 15 0 0 o
80-84 34 0 0 0 15 0 0 0 19 0 0 o
85-89 10 0 0 0 3 0 0 0 7 0
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9.3  Statistical analyses for expected numbers of associated cancers before and 
after tumour of haematopoietic and lymphoid tissues 
The  next  figure  analyses  the  estimated  number  of  AMN  before  and  after  the 
lymphohaematopoietic cancer with a generalized additive model (GAM) for Poisson regression. 
AMN  rates  were  calculated  as  events  per  unit  time  of  age  group  of  diagnosis  of 
lymphohaematopoietic cancer.
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Estimated mean numbers of associated cancers before and after tumour of haematopoietic and 
lymphoid tissues: joint model curves (top) and group specific curves (botttom) among women 
(right) and among men (left) [48]
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